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1. Introduction  
1.1. Adult neurogenesis 
 The renowned Spanish neuroanatomist Ramón y Cajal stated that “Once 
development was ended, the founts of growth and regeneration of the axons and 
dendrites dried up irrevocably. In adult centres, the nerve paths are something fixed 
and immutable: everything may die, nothing may be regenerated” 1. Therefore, it has 
been believed that no new neurons are generated in the adult brain and most of the 
common central nervous system (CNS) pathologies accompanied by neuronal loss 
cannot be restored. Amongst them are well known ones: Parkinson's disease 
accompanied by the degeneration of dopaminergic neurons in the substantia nigra, 
Alzheimer's disease with a neuronal loss in the cerebral cortex and certain 
subcortical regions and stroke where a certain brain area lacks oxygen supply 
followed by neuronal death.  According to the above dogma, the vast majority of 
neurons in the mammalian brain are generated during embryonic development 2, 3. 
This statement stands true for most of the regions of the adult brain. However, this 
doctrine ended in 1965 when newly generated neurons were found in two specific 
regions of the adult brain: the subgranular zone (SGZ) in the dentate gyrus (DG) 
generates new granular neurons in granule cell layer (GCL) of the hippocampus and 
the subventricular zone (SVZ) of the lateral ventricle wall that gives rise to new cells 
that migrate along the rostral migratory stream (RMS) to become neurons in the 
olfactory bulb4, 5 (Fig.1. 1).   
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Fig.1.1. Neurogenic niches in the adult human and in the rat brain. 
The dentate gyrus of the hippocampus and the subventricular zone are known to 
produce new neurons in the adult brain. From the subventricular zone of the lateral 
ventricle cells migrate via the rostral migratory stream to the olfactory bulb, where 
they differentiate into mature neurons and integrate. (Figure extracted from 
www.pubs.niaaa.nih.gov/publications/arh27-2/IMAGES/Page198.gif) 
 
 
1.2. History of adult neurogenesis 
 A study suggested in 1912 by a Canadian scientist Ezra Allen, is considered 
for the preliminary document of mitotic activity in cells of the adult rodent central 
nervous system 6.  Although there were some occasional reports on mitotic cells in 
the brain of adult mammals7 there were no convincing methods to prove that these 
new cells would differentiate into neurons and be functionally integrated. Joseph 
Altman and Gopal Das proposed the concept of persistent neurogenesis in the adult 
brain in 1965 where they used tritiated (H3) thymidine and autoradiography to 
suggest the production of new neurons in the hippocampus8. Later on, it was 
demonstrated through autoradiography and electron microscopy that the newborn 
neurons in the hippocampus were structurally integrated 5, 9. Many advanced 
techniques emerged in the 1990s. Instead of H3 thymidine, bromodeoxyuridine 
(BrdU) and retroviral labelling were used to monitor the newly dividing cells10-15.  
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BrdU can be easily detected with immunohistochemical methods and visualized with 
bright-field and fluorescence microscopes 16, 17. Moreover, combination of the BrdU 
labelling method with specific antibodies against neuronal or glial cell markers has 
allowed the discrimination of newly generated neurons from glial cell type 10, 18, 19. 
With the help of these strategies, adult neurogenesis has been demonstrated in 
numerous mammalian species including humans20, 21.  Finally, the functional 
integration of the newly generated neurons into the existing neural network was 
confirmed demonstrating that these cells participate in long term potentiation (LTP), 
by illustrating synapse formation and expression of immediate early genes after 
stimulation of the hippocampal circuit  16, 22, 23.  
 
1.3. Stem cells in the adult brain 
 In fully matured organisms most of the organs depend on the small local 
population of cells named as adult stem cells or somatic stem cells for their 
maintenance and their regenerative potential. Generally, these stem cell populations 
are established in a defined niche or microenvironment where they remain 
quiescent, proliferate slowly and produce another population of transient amplifying 
precursor cells. These transient amplifying cells are proliferating fast and migrate 
towards the ultimate destination where they undergo differentiation into an 
appropriate functionally mature cell type. Therefore, the potential of adult stem cells 
has to be tightly regulated for tissue homeostasis. In the adult brain new neurons are 
generated from neural stem cells and progenitor cells. These neural stem cells 
(NSCs) are multipotent in nature and have the capacity to self renew and give rise to 
neurons, astrocytes and oligodendrocytes24 (Fig 1.2). These adult stem cells can be 
isolated, expanded in culture and also be transplanted 25.  
4 
 
 
 
 
 
 
Fig.1.2. Multipotential capacity of neural stem cells. 
Neural stem cells (NSC) are multipotent and have the 
capacity to self renew and give rise to lineage-
restricted precursor cells, which further differentiate 
into the three major cell types of the CNS: neurons, 
astrocytes and oligodendrocytes.  
 
 
 
1.4. Hippocampal neurogenesis 
 The hippocampus is a bilateral structure that plays a major role in processing 
and storage of new information. In the hippocampus, stem cells are located along 
the border between the granular cell layer (GCL) and the hi lus known as subgranular 
zone (SGZ), where they produce cluster-forming precursor cells. From there, 
neuroblasts migrate into the GCL and become fully matured functional neurons, 
where they extend dendrites into the molecular layer (ML) and launch mossy fibers 
to the CA3 region 26, 27(Fig. 1.3). Following the principle „do or die‟, the survival 
depends on how sufficiently the new cells are integrated into the neural circuit 28-30. 
From the neural stem cell to the mature neuron the cells go through defined steps of 
division, differentiation, migration and maturation. Using specific markers it is 
possible to investigate the stage specific changes of SGZ neurogenesis in detail 10, 
31. Further, stem and progenitor cells from adult hippocampus produced neurons that 
generated action potentials, received functional GABAergic and glutamatergic 
synaptic inputs32, 33. 
 
5 
 
                                         
Fig.1.3. Processes of neurogenesis in hippocampal DG  
During stage specific event of hippocampal neurogenesis, neural stem cells give rise 
to mature granular neurons through the production and development of intermediate 
precursors cells. (Modified from Encinas JM  et al., 200634) 
 
1.5. Neurogenesis in the SVZ -RMS-OB system 
 The newborn neurons generated in the OB originate from the subventricular 
zone (SVZ) of the lateral ventricle (LV). In the adult brain, newly generated SVZ 
young neurons migrate along the rostral migratory stream (RMS) and proceed to the 
olfactory bulb (OB)35. These neuronal cells integrate upon their arrival into the 
olfactory bulb as specific subtypes of interneurons.  These subtypes are GABAergic 
granule cells, which represent the majority of the new OB neurons, and a very small 
number of  dopaminergic periglomerular interneurons36, 37. The olfactory granule 
cells are inhibitory interneurons that make their dendritic connections to the mitral 
cells and to the middle tufted cells. The periglomerular neurons project their 
dendrites into the corresponding glomerulum and connect to the incoming olfactory 
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axons from the sensory epithelium. It has been shown that these newly formed 
neurons are functionally integrated into the synaptic circuitry of the OB36, 38, 39 (Fig 
1.4).  
 
      
Fig.1.4. Neurogenesis in the SVZ-RMS-OB system 
The DCX promoter EGFP transgenic mouse brain represents neurogenesis in the 
adult olfactory bulb (OB) that is initiated by the persistence of stem cells and 
progenitors in the subventricular zone (SVZ) of the lateral ventricle. The newly 
generated cells migrate through the rostral migratory stream (RMS) and into the 
olfactory bulb, where they differentiate into mature neurons (http://www.uni-
regensburg.de/Fakultaeten/Medizin/Neurologie/forschung/zell.html). 
 
 
 At present, the functional significance of adult neurogenesis is not clear. 
However, many studies have shown that neurogenesis is involved in learning and 
memory. This has led to a hypothesis that suggests impairment in memory during 
aging and neurodegenerative diseases may involve abnormal neurogenesis. In the 
following chapters, these issues will be addressed in more detail. 
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1.6. Regulation of adult neurogenesis 
 Due to the general recognition and acceptance of adult neurogenesis, there 
has been an immense response from the scientific community, resulting in a large 
number of studies investigating how neurogenesis is regulated. Adult neurogenesis 
is a complex multistep process. This process includes proliferation, cell cycle exit, 
fate determination of adult neural progenitors and their differentiation, maturation and 
final integration into the neural circuits 23. Although, the precise mechanisms that 
generate new neurons in the adult brain remain elusive, a range of environmental-, 
behavioral-, genetic-, neuroendocrine-, neurochemical- and growth factors as well as 
cytokines have been shown to be involved in the regulation of adult neurogenesis.  
A number of stimuli have been shown to influence neurogenesis: in an enriched 
environment the animals are kept in housing conditions that are more similar to their 
natural environment. Such an enriched condition has given rise to increased 
neurogenesis and seems to play a neuroprotective role for newly generated neurons 
40-42. Similar to enriched environmental conditions, wheel running- physical exercise 
has also been shown to boost hippocampal neurogenesis drastically through an 
increasing rate of progenitor proliferation16, 43. The animals that were exposed to an 
enriched environment and physical exercise showed improved motor skills and 
better performance in learning tasks 16, 40. Stroke, a pathological situation in which 
blood supply to the brain is suddenly disrupted. It has been shown that stroke also 
stimulates the generation of new neurons44. Epileptic seizure is another pathological 
situation, which arises from the abnormal excitation of neuronal networks in the 
brain. This epileptic pathological process has also been shown to provoke 
neurogenesis in the adult brain45.  Fluoxetine is an antidepressant drug that has 
recently been shown to improve neurogenesis during young adulthood46.  
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 Besides, it has been shown that neurogenesis in the hippocampus decreases 
with age, although in very old animals, there still remains a low-level of 
neurogenesis19, 46. Stress is a physiological response to any kind of unpleasant 
events that provoke the hypothalamic pituitary axis (HPA) and raise the release and 
circulation of adrenal steroid hormones. Adrenal steroids may be one of the most 
important neurochemical regulators of neurogenesis. An increased plasma level of 
corticosterone, as it appears as a reaction to applied stress, has negative effects on 
hippocampal neurogenesis47-49. However, this stress induced inhibition of precursor 
cell proliferation has been shown to be prevented by systemic administration of 
prolactin (PRL) 50. 
 
1.7. Regulation of adult neurogenesis by signaling molecules  
 In mammalian tissue, typical homeostasis requires elaborately balanced 
interactions between cells and the network of secreted proteins. These reciprocal 
communications involve various extracellular cytokines acting via specific cell 
surface receptors. When the balance between the cells and the extracellular 
communication is dysregulated, pathogenesis can result 51. Growth factors are 
capable of controlling cellular growth, differentiation, maturation and survival. 
Numerous studies have been carried out to demonstrate that progenitors in the adult 
brain respond to growth factors. Intracerebroventricular infusion of epidermal growth 
factor (EGF) and fibroblast growth factor-2 (FGF-2) increased proliferation in the 
SVZ of the adult rats brain 31. Also insulin-like growth factor-1 (IGF-1) seems to be 
involved in the regulation of adult neurogenesis. Plasma levels of IGF-1 are 
increased by exercise and this promotes major increases in GCL precursor 
proliferation52. Moreover, other studies have demonstrated that intracerebral infusion 
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of IGF increases both cell proliferation and neurogenesis in hypophysectomized rats  
53. Like IGF-1, vascular endothelial growth factor (VEGF) also has a stimulatory 
effect on neurogenesis54. Furthermore, a recent report demonstrated that 
granulocyte colony-stimulating factor (G-CSF) promotes proliferation of neural 
progenitors 55.  
 In contrast, members of the family of transforming growth factor beta (TGF-
beta) are known to inhibit neurogenesis by blocking the proliferation of precursor 
cells in the adult brain. Therefore, TGF-betas and their downstream signaling are at 
the focus of attention to elucidate their involvement in adult neurogenesis. Bone 
morphogenic proteins (BMP) are extracellular signaling molecules that play diverging 
roles in neuronal development. Generally, the BMP molecules are characterized by 
their antagonistic action on neurogenesis.  Noggin, e.g., is a soluble inhibitor for the 
BMP4 signal that promotes neurogenesis by blocking the BMP4 influence on stem 
cell proliferation56.  
 
1.8. Transforming growth factors 
 The TGF gene family expresses a set of structurally and functionally related 
polypeptides that include activins, bone morphogenic proteins (BMPs), the growth 
differentiation factors (GDFs), and a small group of pleotrophic cytokines, the TGF-
beta molecules57, 58. The TGF-beta name was coined in the year 1981 because of its 
transforming effect on rat kidney and fibroblast cell lines59-61. TGF-betas have been 
implicated in cell proliferation, differentiation, migration, survival, apoptosis, 
extracellular matrix (ECM) formation, angiogenesis, metastasis, tumorogenesis, 
inflammation and tissue repair 58. There are three highly homologous isoforms of 
TGF-beta molecules: TGF-beta1, TGF-beta2 and TGF-beta3. Each of these three 
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isoform genes encodes an inactive precursor protein. Sequential processing to gives 
rise to the active TGF beta ligand. From the 391-amino-acid precursor form of TGF-
beta1, the C-terminal 112 amino acids comprise the mature protein. The N-terminal 
peptide is the pro-domain, called the latency associated peptide (LAP). TGF-beta is 
secreted as a large latent complex composed of the active TGF-beta form covalently 
bound to LAP, which in turn is bound to a latent TGF-beta-binding protein (LTBP). 
Since the LTBP is linked to the extracellular matrix (ECM), the entire complex is 
stored in the extracellular space and provides a source of readily available ligand. 
Extracellular serine proteases cleave the LTBP and release the active ligand from 
LAP 57, 62. The biologically active form of TGF-beta consists of a homodimer built out 
of two peptides each in size of 12.5 kD, which are linked through disulfide bonds63, 64.  
 
1.8.1. The TGF-beta signaling pathway 
 The TGF-beta family members bind to their cognate heteromeric receptor 
complex, which consists of two types of transmembrane serine/threonine kinases 
known as type I (TGF-betaRI or ALK) and type II receptors (TGF-betaRII)65, 66. These 
transmembrane receptors represent two families of serine/threonine kinase 
receptors of 53 to 65 kD and 80 to 95 kD, respectively. In mammals five isoforms of 
TGF-betaRI and seven isoforms of TGF-betaRII were identified. TGF-betaRIII 
(betaglycan and endoglin) is an indirectly signaling mediator which promotes the 
affinity of TGF-betaRII for TGF-beta2. In contrast, TGF-beta1 and TGF-beta3 bind 
directly to TGF-betaRII, a constitutively active kinase that leads to dimerization with 
the type I receptor and phosphorylation of the glycine-serine (GS) domain. 
Phosphorylation of the GS domain activates the C-terminal kinase domain, which 
phosphorylates and thereby activates receptor Smads (homologous proteins to the 
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Sma and Mad proteins from Caenorhabditis elegans and Drosophila melanogaster 
(R-Smads)). Characteristically, all Smad proteins possess two domains, the MH1 
and MH2 (mad homology) domains, the MH1 domain is located on the amino-
terminus and the MH2 domain is located on the carboxy-terminus. Functionally, the 
MH1 is involved in protein-DNA interaction whereas the MH2 being responsible for 
the protein-protein interaction. Accordingly TGF-beta activates the phosphorylation 
of Smad2 and Smad3 while BMPs activates the phosphorylation of Smad1, Smad5 
and Smad8. The phosphorylated R-Smads dimerize with Co-Smad (Smad4) and 
transloctate to the cell nucleus where they exert their function as transcription 
factors. TGF-beta1 stimulation leads to the nuclear translocation of the 
phosphorylated Smad 2/3 and of the Co-Smad 4 complex that activates the inhibitory 
I-Smads (Smad6 and Smad7). These activated I–Smads act as an antagonist for 
TGF-betaRI mediated downstream signal by blocking the receptor accessibility to R-
Smads ( Fig 1.5) 57, 58, 67, 68. 
                               
Fig.1.5. Receptor mediated TGF-beta1 signaling 
TGF-beta ligand binds to TGF-betaRII that complexes with and activates TGF-
betaRI. This induces the downstream Smad-mediated signal transduction (Aigner 
and Bogdahn, 2008). 
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1.8.2. TGF-beta expression in the normal and pathological brain  
 TGF-betas are involved in various physiological and pathological processes in 
the CNS.  All three isoforms of TGF-beta are expressed within the nervous system, 
in neurons and in glial cells58, 69, 70. Most of the current knowledge about the 
expression of TGF-beta in the CNS comes from studies of the development. In the 
adult, TGF-beta2 and TGF-beta3 can be found in all areas of the CNS58.  TGF-beta1 
is widely expressed in the choroid plexus and in the meninges and its expression is 
drastically up regulated, in the CNS during injury and neurodegeneration71-74 where it 
is secreted predominantly by activated microglial cells75. In addition, cultivated 
neurons and astrocytes have been shown to secret TGF-beta176. In brain pathology, 
TGF-beta1 is involved in coordinating the inflammatory responses and brain 
recovery. TGF-beta1 and TGF-beta2 are also involved in brain-tumor development 
and progression, in particular of high-grade gliomas 58, 77-81. 
 
1.8.3. TGF-beta signal transduction in the brain 
 TGF-beta receptors are expressed in the brain69, 82. Expression of TGF-
betaRII mRNA is clearly reported in most of the brain areas such as cerebral cortex, 
midbrain, cerebellum, and brainstem58, 69. Concerning the cell type specificity it is 
expressed in neurons, astroglia, microglia, endothelial cells, and other non-neuronal 
cells found in the choroid plexus58, 83, 84. Surprisingly, in a recent in vivo imaging 
study from the group of Wyss-Coray on a Smad-responsive luciferase transgenic 
mouse, a high level of downstream signaling activity of TGF-beta was noticed in the 
intact adult brain85. Subsequently, it was demonstrated that the expression of TGF-
betaRI and II mRNA and of the TGF-betaRII protein in neural stem  and progenitor 
cells isolated from the SVZ of the adult brain 82. 
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1.8.4. Role of TGF-beta in the brain  
 TGF-beta displays diverse functions in the adult brain. TGF-beta1 is a global 
immune modulator and it plays a crucial role in neuroprotection. TGF-beta1 has 
been shown to promote the survival of neurons 86-88. In addition to its other effects 
and probably depending upon its discrete cellular environment, TGF-beta1 inhibits 
proliferation of astrocytes but induces their differentiation89. TGF-beta1 has been 
shown also to exert a negative effect on the proliferation o f microglia 90. 
 
1.8.5. Regulation of adult neurogenesis by TGF-beta1 
 Recently, the regulation of adult neurogenesis by experimentally induced level 
of TGF-beta1 was demonstrated. Thus infusion of TGF-beta1 into the ventricles of 
adult rat brain revealed a reduced amount of proliferating cells in the hippocampus 
and in the SVZ. Further, infusion of TGF-beta1 lowered the number of DCX 
expressing neuronal precursor in these neurognic niches. Besides, in an in vitro 
study treatment of TGF-beta1 in the neurosphere cultures reduced the proliferation 
of stem cell and progenitor cells and induced a shift to G0 phase of the cell cycle 82. 
Subsequently, a study from the Wyss Coray group has confirmed these findings in 
the brains of  transgenic animals, that over-express TGF-beta1 under the control of 
the glial fibrillary acidic protein promoter in astrocytes91.  In addition, other reports 
mainly focused on the intermediate and late stages of the neurogenic processes and 
described that TGF-beta1 elevates neuronal differentiation and survival. For 
example, injection of adenoviral vectors expressing TGF-beta1 into the SVZ of the 
adult rats brain increased the expansion of DCX-expressing newly born immature 
neurons92. Intranasal administration of TGF-beta1 in adult mice after stroke 
promoted the number of newborn DCX and NeuN positive neurons via reducing the 
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cell death process93. There is an increased number of newly born PSA-NCAM 
positive neurons in the hippocampus of adrenalectomized rats brain where it has 
been correlated with an induced secretion of TGF-beta 1 by activated microglia94. 
Moreover, TGF-beta1 is an important neuroprotective factor that can prevent 
neuronal damage from almost all kind of brain damage including neurodegenerative 
disease72, 86, 95, 96.  
 
1.8.6. Enhanced TGF-beta1 levels and impaired neurogenesis in 
neurodegenerative disorders 
 
 Neurodegenerative disorders are devastating hereditary and sporadic 
conditions which are characterized by progressive loss of neuron structure and -
function, ultimately leading to the death of selective neuronal populations in specific 
brain areas. Many neurodegenerative disorders including Alzheimer`s disease (AD), 
Parkinson‟s disease (PD) and Huntington‟s disease (HD) occur as a result of 
degeneration of neurons due to the toxicity of protein aggregation. So far no 
promising treatments are available to eradicate these disease conditions. During 
past decades series of reports have demonstrated impaired neurogenesis in the 
brain under degenerative conditions occurring with diseases such as AD, PD and 
HD97-99. Therefore, understanding the regulation of neurogenesis in degenerative 
brains is of crucial importance for therapeutic intervention. In most of the 
neuropathological conditions, it has been shown that specifically the inflammatory 
cytokines and their downstream signaling are altered83. For example, while 
neurogenesis is impaired in the diseased brain of patients with AD and HD, the 
pleiotropic cytokine TGF-beta1 and their downstream signaling components are 
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elevated  71, 96. This alteration in cytokine expression and its subsequent signaling 
cascades might be playing a crucial role in impaired neurogenesis. Therefore, in the 
following chapters some key issues of the pathologies of Huntington‟s disease will be 
described. 
 
1.9. Huntington’s disease 
 Huntington's disease, also termed Huntington chorea is an inherited 
autosomal dominant disorder resulting from an expansion of the CAG repeats within 
the Huntington gene (Htt) located on chromosome 4100. The expansion of the CAG 
repeats causes polyglutamine stretches on the huntintin protein that induces 
progressive degeneration of neurons primarily in the striatum and in the cortex101. 
This neuronal loss leads to cognitive deficits, impaired motor functions and 
psychiatric disturbances102, 103. Thus far there are no treatments available to alleviate 
this devastating disease.   
 
1.9.1. Clinical aspects of Huntington’s disease  
 Huntington‟s disease is a progressive neurodegenerative disorder 
characterized by chorea, involuntary body movements and dementia. Psychiatric 
symptoms like depression are known to occur during the onset of disease104. In 
general, the mood changes, irritability, anger and depression are commonly 
observed with minimal motor skills. As HD progresses, the physical, intellectual and 
emotional symptoms become more severe. In most of the cases, characteristic 
choreiform movements of the head, neck, arms and legs are more visible. In juvenile 
forms of HD, the patient will often suffer from muscle rigidity and bradykinesia 
without showing symptoms for chorea105. These conditions are known as „Westphal 
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variant‟ of HD and affect 6% of HD patients106. Weight loss is one of the features of 
progressed form of HD due to poor food intake.107, 108  As a result of vulnerable 
dementia and progressive motor dysfunction, patients with advanced HD may 
become unable to walk, have poor dietary intake108, eventually arrest in locomotion 
and become unable to care for themselves, eventually requiring long-term intensive 
care. Final and fatal complications may result from pathology related to serious falls, 
poor nutrition, infection, choking, inflammation of the lungs and heart failure  
(http://hdlighthouse.org).  
 
 1.9.2. History of Huntington’s disease  
 The word chorea in Greek means dance. It referres to the classes of 
movement disorders caused by destruction of the basal ganglia and describes the 
associated uncontrolled body movements. The first observation of chorea in  
childhood was reported by a British physician, Thomas Sydenham (1624-1689), but 
it was distinct from Huntington's disease and associated with rheumatic fever also 
know as Sydenham chorea and as St. Vitus' dance.  Later on, Huntington‟s disease 
or Huntington's chorea was precisely described as an uncontrolled movement 
disorder in association with dementia in 1872 by George Summer Huntington, an 
American physician (Fig 1.6). While chorea movement disorders had been well 
recognized, Huntington‟s disease expels unique features like the hereditary in 
nature, mutation in Htt, late onset and neuronal loss in the striatum and the cortex. 
Huntington‟s disease is primarily an adult disorder, with an average onset between 
35 and 42 years109.  However, the disease can encounter at any age and 6% are 
juvenile forms110. The age of onset is closely correlated with the CAG repeat length 
of the mutant form of the htt gene111.  
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Fig.1.6. A photograph of George Summer Huntington 
(1850-1916)  
Born (1850) in East Hampton, New York, USA –died 
(1916) in Cairo, New York, USA(Okun, 2003). 
(http://medinfo.ufl.edu/other/histmed/okun/images/05.jpg) 
 
 
 
 
1.9.3. Epidemiology of Huntington’s disease  
 Huntington‟s disease is the most prevalent disorder in a family of several 
neurodegenerative diseases that are caused by a poly-glutamine expansion in the 
huntingtin protein. HD affects male and female with the same frequency112. The 
highest prevalence is in Europe and North America, with 4-8 cases per 100000 
people113. Venezuela has the highest HD population in the world 114.  This emerged 
to build the foundation of the Venezuela Huntington‟s disease organization, which 
ultimately led to the identification of a transcript called IT15 (interesting transcript 15) 
located on the 4th chromosome which was shown to be associated with Huntington‟s 
disease115. Ten years later, in 1993, the gene was isolated and characterized and  
then called the HD gene or huntingtin (htt) by The Huntington's Disease 
Collaborative Research Group. Mutations in the htt gene give raise to  the 
polyglutamine stretches  in the N-terminal region of the huntingtin protein100.  
 
1.9.4. Localization and function of the physiological Huntingtin protein 
 The human huntington gene contains 67 exons spanning around 200 kb in 
size and is located in the p arm of chromosome 4 at position 4p16.3 (Fig 1.7). This 
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gene contains a particular DNA segment known as a CAG trinucleotide repeat. This 
segment is made up of a series of three DNA building blocks (Cytosine, Adenine and 
Guanine) that appear multiple times in a row100. Normal individuals have 10 to 35 
CAG segment repeats.  People with 36 to 40 CAG repeats may or may not develop 
the signs and symptoms of Huntington‟s disease while people with more than 40 
repeats have an almost 100% possibility to develop the disorder112, 116. Htt has very 
rare homology to other proteins and its functions are poorly understood.           
 
 
    
 
 
 
 
 
 
 
Fig.1.7. Location of the huntingtin gene 
Human chromosome 4 with the location of the HD gene 
indicated at the top of the short arm. 
(http://ghr.nlm.nih.gov/dynamicImages/chromomap/htt.jpeg) 
 
 
 Htt is widely expressed within the body with the highest levels in the brain and 
the testis. Within the brain regions, it can be found in highest levels in the cerebellar 
cortex, the striatum and the hippocampus117, 118. While the direct function of htt is not 
yet known, it is apparently required for normal embryogenesis, since htt knockout 
animals die at an early developmental stage119. Conditional knockout studies have 
demonstrated that htt plays an essential role during postnatal development, as the 
inactivation of the gene in the brain and in the testis leads to degeneration of these 
two organs120. Furthermore, htt is required for neuronal survival120-122. There are 
19 
 
significant numbers of protein partners that interact with the huntingtin protein. The 
mainly known htt interaction proteins are involved in transcription and cellular 
trafficking. At present, around 100 interacting proteins have been listed to interact 
with huntingtin protein. From the list, huntingtin-associated protein 1 (HAP1) and 
huntingtin Interacting Protein 1 (HIP1) are extensively characterized for their 
interaction with htt123, 124. Concerning the neuronal survival, normal huntingtin protein 
known to up-regulate transcription and traffic of BDNF through its interaction with 
HAP1125 but the underlying molecular mechanisms that controls the expression of 
BDNF are not clear.  
 
1.9.5. Expanded CAG repeats in the huntingtin gene 
 In the HD gene, the number of CAG repeats plays a critical role for its 
functions. More than 40 CAG repeats in the HD allele definitively lead to a mis 
folding, loss of function and toxic protein aggregation. The  increase in length of CAG 
repeats correlates with fast onset and high grade of HD pathology116. However, the 
mechanism of polyglutamine expansion and its pathogenic role are unclear. In 
neurons, it has been proposed that missfolded htt aggregates translocate to nuclei 
and form neuronal inclusions (NI) and induce caspase mediated apoptotic cell death 
pathways126, 127.  Recent studies have shown that altered huntingtin can trap some 
proteins and dislocate them from their original locations thus preventing them from 
functioning within nerve cells128. Thus a study showed that Htt interferes with the 
function of CREB-binding protein 129.  
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1.9.6. Neuropathological hallmarks of HD 
 The loss of neurons in the HD brain starts in the striatal region. The striatum is 
the part of basal ganglia that contains medium spiny projecting neurons (MSN)130. In 
the HD brain, these neurons are most severely affected, resulting in atrophy of the 
striatum, first in the caudate nucleus, then in the putamen. The second hot spot of 
neurodegeration in HD is the cortex. Neurons in layer V and VI o f the cortex 
projecting to the striatum are mostly affected. Characteristic polyQ protein 
aggregates are accounted for dysfunctions in the HD brain131. These aggregates, 
which are ubiquitinated, are called neuronal nuclear inclusions (NII) or dystrophic 
neuritic inclusions (DNIs), depending on their sub-cellular localization. Inclusions are 
mainly found in the striatum and in the cortex132, 133. Their direct effect on the 
neurodegeneration is still under debate, as both defensive and toxic functions have 
been described in HD but also in other neurodegenerative diseases such as the 
Lewy bodies in Parkinson‟s disease and the amyloidal plaques in Alzheimer‟s 
disease. 
 Pathological hallmarks of HD include marked decreases in volume in both the 
caudate nucleus and putamen, leading to the significant increase in lateral ventricle 
volume134, 135. There are some studies using MRI techniques in HD patients that 
have also indicated extrastriatal differences, for example hippocampal atrophy 136. 
Hippocampal atrophy and hippocampal dysfunction are the most common 
abnormalities in cognitive deficits. Significant hippocampal volume loss has been 
found in most of the patients with comorbid depression137. However in HD pathology, 
the effects of hippocampal volume loss on comorbidity and cognitive decline have 
not yet been studied in detail.  
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1.9.7. Experimental models of Huntington’s disease  
1.9.7.1. Acute models for Huntington’s disease  
 Injection of amino acids such as N-methyl- D-aspartate (NMDA), quinolinic 
acid, and 3-nitro propionic acid into animals leads to neuronal loss  in different 
regions of the brain including the striatum that is believed to be relevant with HD 
pathology138-140. These chemicals are known to accelerate glutamate receptor 
activation and cause mitochondrial dysfunction in neurons of the striatum. These 
chemically induced models are still useful tools to test therapeutic strategies which 
can delineate the acute neuronal loss in the striatum. However these models do not 
mirror the progressive chronic neuronal degeneration and molecular changes along 
the disease progression.  
 
1.9.7.2. Transgenic models of Huntington’s disease  
 For HD, several transgenic models have been developed in different 
organisms ranging from nematodes to primates. The nematode Caenorhabditis 
elegans is the simplest genetic animal model of PolyQ neurotoxicity, in which the N-
terminal 171 amino acid fragment of human huntingtin protein containing an 
expanded polyglutamine tract (150Qs) is expressed in neurons and this model 
displays neurodegeneration141. PolyQ-expressing fruit flies form nuclear inclusions 
and undergo a progressive neurodegeneration142, 143. The major breakthrough in the 
field of Huntington‟s disease has from the development of transgenic lines that 
express the exon1 of htt with 115 CAG (R6/1) or 155 CAG (R6/2) repeats and 
develop progressive behavioural symptoms and neuropathology144. These animals 
display an early onset of HD pathology, have a shorter life span and die within the 
first two to four months144. Recently, a transgenic rat model of Huntington‟s 
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disease(tg HD rat) was developed by von Hörsten and colleagues135. This model 
carries a truncated huntingtin cDNA fragment encoding for 51 CAG repeats under 
the control of the rat huntingtin promoter. TgHD rats exhibit an adult-onset of the 
neurological HD phenotype characterized by elevated anxiety, cognitive impairment 
and slowly progressive motor dysfunction. Furthermore, these behavioral 
manifestations are accompanied by typical histo-pathological alterations such as NII 
in the basal ganglia and in the hippocampus132, 135. Besides, tgHD rats suffer from 
brain mitochondrial dysfunction and degeneration of medium spiny neurons71, 145. In 
addition to their progressive behavioural impairments and neuropathological signs, 
tgHD rats have an increased lethality starting at about 15 months of age. The slowly 
evolving pathology thus reflects more faithfully the human HD condition and permits 
a detailed analysis of progressive alterations in the brain organization and 
function132, 135. Moreover, it provides a window of opportunity to scrutinize the impact 
of endogenous or induced cellular plasticity and/or restorative processes during 
various phases in the course of the pathology.  
 
1.9.8. Neurogenesis in Huntington’s disease  
 In the context of Huntington‟s disease, it has been shown that neurogenesis is 
impaired in the hippocampus of transgenic R6 mouse lines of Huntington‟s 
disease144 but it is increased in the SVZ of chemically induced acute models of the 
disease146 and HD patients147. However, the impairment of adult neurogenesis at 
different stages of the disease progression in the HD brain has been not 
characterized. Hence, this study aims to characterize the regulation of hippocampal 
neurogenesis in different clinical phases of HD by using a transgenic HD rat model 
which resembles the human HD pathology. 
23 
 
2. Aim of the study 
 In the mammalian brain, new neurons are continuously generated in the 
hippocampus and in the SVZ throughout the adulthood. This process includes neural 
stem and progenitor cells maintenance, proliferation, neuronal differentiation, 
neuronal integration and survival. The exact molecular cues governing neurogenesis 
in these distinctive neurogenic niches are not known. The main objective of this 
thesis is to address the role of TGF-beta1 in regulation of adult neurogenesis in the 
normal brain and in the degenerative brain. This study was focused on the 
characterization of the endogenous level of receptor mediated TGF-beta1 signaling 
in the stem cell niche of the healthy brain.  The stem and progenitors cells in the 
neurogenic niche are elaborately analyzed for the TGF-beta1 signaling in association 
with their cell proliferative and differentiation potentials. Further, the normal adult 
stem cell niche was challenged with elevated levels of TGF-beta1 by using the 
intracerebroventricular infusion and transgenic animal model systems. Therefore, it 
allows measuring the influence of TGF-beta1 on the regulation of stem and 
progenitor cells in the context of neurogenesis per se.  
 Adult neurogenesis is inhibited in neurodegenerative disorder such as 
Huntington‟s disease but the progression of cellular events and molecular 
mechanisms that influence neurogenesis in HD brain are poorly understood. 
Strikingly, the expression of TGF-beta1 and TGF-beta signaling components are 
elevated in the degenerating HD brain.  Therefore, we hypothesize that TGF-beta1 
might be involved in the stem cell niche remodelling in HD brains. Hence, the 
present study investigated the regulation of neurogenesis in transgenic HD models 
at different clinical phases and scrutinized a correlation between observed 
neurogenic modulations and alterations in TGF-beta signaling. 
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3. Methods 
3.1 Materials 
3.1.1 Expendable materials 
Osmotic minipumps   ALZET, Durect Corp., Cupertino, USA 
BD Discardit™ II syringes   Becton Dickinson, Heidelberg 
BD Plastikpak™ syringes (1ml)  Becton Dickinson, Heidelberg 
Cell culture flasks (50ml, 250ml, 500ml)  TPP, Switzerland 
  Greiner Bio-One GmbH, Frickenhausen 
Combitips  Eppendorf, Hamburg 
Cover glasses Menzel ( 13mm)  VWR, Darmstadt  
Disposable gloves  Hartman, Heidenheim 
  Semperit Austria 
Cryo Tubes  Nunc, Denmark 
Hyperfilm   AmershamPharmacia, Freiburg, Germany 
Microscope slides  Menzel GmbH & Co KG, Braunschweig 
Nitrocellulose membrane   Schleicher and Schuell, Dassel, Germany. 
Pipette tips     Sarstedt, Nürmbrecht 
Pipette tips with filter  Biozym, Hessisch Oldendorf 
Syringe-Filter (0.22µm)  TPP, Switzerland 
Scalpels  
Test plates (6-well, 24-well, 96-well)  Omnilab, Schubert & Weiß, München 
                                      TPP, Switzerland 
Tubes  Eppendorf, Hamburg 
  Falcon BD, Heidelberg 
  Gibco BRL, Karlsruhe 
                                                                 Sarstedt, Nümbrecht 
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3.1.2 Chemicals for in vivo immunological procedure  
 
Acepromazine WDT, Garbsen, Germany   
Vectastain Elite ABC kit Vector Laboratories, Burlingame, USA 
BrdU Sigma-Aldrich, Taufkirchen 
BSA Sigma-Aldrich, Taufkirchen 
3,3'-Diaminobenzidine (DAB) Vector Laboratories, Burlingame, USA 
Ethylene glycol AppliChem, Darmstadt 
Formamide Merck, Darmstadt 
Glycerol AppliChem, Darmstadt 
HCl Merck, Darmstadt 
H2O2  Vector Laboratories, Burlingame, USA 
 Merck, Darmstadt 
Ketamine WDT, Garbsen, Germany 
Methanol Merck, Darmstadt  
NaCl Sigma-Aldrich, Taufkirchen 
NaOH Sigma-Aldrich, Taufkirchen 
NaH2PO4 Merck, Darmstadt 
Na2HPO4 Merck, Darmstadt    
Nuclear Merck, Darmstadt 
Neo-Mount Merck, Darmstadt 
Nicl2  Vector Laboratories, Burlingame, USA 
Paraformaldehyde (PFA) Sigma-Aldrich, Taufkirchen 
Prolong Antifade kit Invitrogen Molecular Probes™ Eugene, 
Oregon, USA 
Teleostean gelatin  Sigma-Aldrich, Taufkirchen 
Topro3 Molecular Probes, USA 
Triton X 100 Sigma-Aldrich, Taufkirchen 
Sucrose Sigma-Aldrich, Taufkirchen 
Tissue Tek  Sakura finetek, USA 
Tris-Base Sigma-Aldrich, Taufkirchen 
xylazine  WDT, Garbsen, Germany 
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3.1.3 Chemicals for Western blot  
 
30% Acryamide/Bisacryamide solution Sigma-Aldrich, Taufkirchen 
Ammonium Persulfate (APS) Sigma-Aldrich, Taufkirchen 
Aprotinin  Sigma-Aldrich, Taufkirchen 
Bovine Serum Albumine (BSA) Sigma-Aldrich, Taufkirchen 
Bicinonic Acid (Lowry) Sigma-Aldrich, Taufkirchen 
Bromphenol Blue Sigma-Aldrich, Taufkirchen 
Copper Sulfate Sigma-Aldrich, Taufkirchen  
Dithiothreitol (DTT) Sigma-Aldrich, Taufkirchen 
ECL plus Amersham Pharmacia, Freiburg, Germany 
EDTA Merck, Darmstadt 
Ethanol Merck-Schuchard, Hohenbrunn 
Glycin Merck, Darmstadt 
Beta-Mercaptoethanol Sigma-Aldrich, Taufkirchen 
SDS Merck-Schuchard, Hohenbrunn 
Tetramethylethylenediamine (TEMED)  Sigma-Aldrich, Taufkirchen 
Tween-20 Sigma-Aldrich, Taufkirchen 
NP40 (IGEPAL) Sigma-Aldrich, Taufkirchen 
Ponceau Solution  Sigma, Germany 
PMSF  Sigma-Aldrich, Taufkirchen 
Pepstatin  Sigma-Aldrich, Taufkirchen 
Protease inhibitors  Invitrogen,USA 
 
3.1.4 Cell culture medias   
Proliferation media 
Neurobasal Medium (Gibco, Karlsruhe) containing:  
 
100µg/ml Penicillin/Streptomycin PAN Biotech GmbH, Aidenbach, Germany 
200mM Glutamin PAN Biotech GmbH, Aidenbach, Germany 
1x B27 Gibco BRL, Karlsruhe, Germany 
20ng/ml Fibroblast Growth Factor-2  R&D Systems, Wiesbaden-Nordenstadt, 
Germany 
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20ng/ml Epidermal Growth Factor  R&D Systems, Wiesbaden-Nordenstadt, 
Germany 
2µg/ml Heparin  Sigma-Aldrich, Taufkirchen, Germany 
 
Differentiation media 
Neurobasal Medium Gibco containing: 
1x B27 Gibco BRL, Karlsruhe, Germany 
100µg/ml Penicillin/Streptomycin PAN Biotech GmbH, Aidenbach, Germany 
200mM Glutamin PAN Biotech GmbH, Aidenbach, Germany 
5% Fetal Calf Serum (FCS) PAN Biotech GmbH, Aidenbach, Germany 
 
3.1.5. Other reagents for cell culture 
Accutase PAA, Pasching, Austria 
Bone Morphogenic Protein 2/4     R&D Systems GmbH, Wiesbaden-
Nordenstadt 
Bromphenol Blue             Sigma-Aldrich, Taufkirchen 
B27 supplement  Gibco BRL, Germany 
Dispase II  Boehringer, Germany 
DMEM/F12  Gibco BRL, Germany 
Dnase I  Worthington Biochemicals, England 
Dulbecco‟s phosphate buffered saline  Sigma, Germany 
Dulbecco‟s PBS Gibco, Karlsruhe 
Fetal calf serum (FCS)  PAN, Germany 
Glucose  Merck, Germany 
Hank‟s Balanced Salt Solution  PAN, Germany 
Heparin  Sigma, Germany 
IMEM  Gibco BRL, Germany 
Laminin  Sigma, Germany 
L-glutamine  PAN, Germany 
Neurobasal Medium (NB)  Gibco BRL, Germany 
Papain  Worthington Biochemicals, England 
Penicillin/streptomycin  PAN, Germany 
Poly-L-ornithine  Sigma, Germany 
Trypan Blue  Sigma, Germany 
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Trypsin  PAN, Germany 
 
 
3.1.6 Buffer, solutions and stock solutions 
Tris Buffered Saline (TBS) 800 ml dH2O 
 8g NaCl 
 3g Trisbase  
 HCl adjust to pH 7.4  
 
Borate Buffer (0.1M)  3.08g boric acid 
  450 ml H2O 
  5N NaOH to pH 8.5 
  Final volume to 500 ml 
 
PBS (0.1M)  500ml 0.2M Phosphate Buffer 
  500ml dH2O 
  9g Natriumchloride 
 
Phosphate Buffer (0.2M)   1L dH2O 
 5.52g NaH2PO4, water free 
  21.9g Na2HPO4, water free 
                                                                10ml 10xPBS  
 
Cryo Protective solution  250 ml Glycerin 
 250 ml Ethylenglycol 
 500 ml 0.1M PO4 buffer. 
 
Fish Skin Gelatin Buffer (FSGB) 0.1M Tris-HCl, pH 7.5 
 0.15M NaCl 
 1% w/v BSA 
 0.2% v/v Fish Skin Gelatin 
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 0.1% v/v Triton X-100 
 
DAB solution 0.25 mg/ml 3, 3′-diaminobenzidine 
 0.01% (v/v) H2O2,  
 0.04% (w/v) NiCl2   
 
Donkey serum blocking buffer 0.1 M Tris-Hcl, pH 7.5 
  0.15 M NaCl 
 3% donkey serum 
 0.1% Triton X-100 
 
4% Paraformaldehyde (PFA) 250 ml dH20  
For perfusion 0.5 ml 10M NaOH 
 20 g PFA 
 250 ml 0.2M PO4 buffer 
 
4% Paraformaldehyde (PFA) 4% PFA 
For fixation of cells 2.5mM NaOH 
 0.4mM CaCl2 
 50mM Sucrose 
 0.1M NaH2PO4 
 
Protein Isolation Buffer 0.7% IGEPAL 
(Fei He et al. 2005 modified) 50mM Tris HCl, pH 8.0 
 0.1mm EDTA pH 8.0 
 250mM NaCl 
 10% Glycerol 
 0.2mm Na2VO4 
 50mM NaF 
 1mM PMSF 
 10mM DTT 
 Protease inhibitors 
 
Sample buffer for proteins-WB 1M Tris-HCl, pH 6.8 
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 1% SDS 
 30% Glycerol 
 DTT 
 2% bromophenol blue 
 
Resolving gel buffer -WB 2M Tris-HCl pH 8.0 
 10% SDS 
 H2O bidest 
 
Stacking gel buffer -WB 1M Tris-Cl, pH 6.8 
 10% SDS 
 H2O bidest 
 
Electrophoresis buffer (1L)-WB 25mM Tris Base (3g) 
 14,4g Glycin 
 1% SDS  
 
Blotting Buffer-WB 25mM Tris Base (3,03g/L) 
 150mM Glycine (11,26g/L) 
 
PPD (100 ml)   0.01% Papain 
  0.1% Dispase II 
  0.01% Dnase I 
  149 mg MgSo4*7H2O in Hank‟s Balanced 
Salt Solution w/o Ca2+/Mg2+ 
 
Running buffer for WB  3.02g Tris-Base 
 14.4g glycerin 
  1.0g SDS 
  dissolve in 0.8l H2O, set at pH 8,3 with 2M 
HCl and fill up to 1l with H2O 
 
30% Succrose   400ml 0.1M PO4 
  150g Sucrose  
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SSC  3.0M NaCl 
  0.3M NaCl x 2H2O 
 QS 500ml H2O, pH 7.0 
 
TBST  TBS+0.25% TWEEN 
 
3.1.6. Primary antibodies 
 
List of Antibodies Marker Dilution 
for 
Histology 
Dilution 
for 
WB 
Source 
Rat anti-BrdU Base analogue 1:500  Oxford Biotechnology, 
UK. 
Mouse anti-PCNA Proliferation 1:500  Santa Cruz, USA 
Rabbit anti-GFAP Astrocytes 1:100  Dako, Denmark 
Guinea pig anti-
GFAP 
Astrocytes 1:500  Progene, Germany 
Mouse anti rat-Nestin Stem cell 1:500  Pharmingen, USA 
Goat anti-Sox2 Stem cell 1:500  Santa Cruz, USA 
IgM mouse anti-A2B5 Glial  progenitor 1:200  Chemicon, USA 
Rabbit anti-DCX Neuroblast 1:500  Chemicon, USA 
Goat anti-DCX Neuroblast 1:2000  Santa Cruz, USA 
Mouse anti-MAP2ab Neuron 1:500  Sigma, Germany 
Mouse anti-NeuN Neuron 1:500  Chemicon, USA 
Mouse anti-MBP Oligodendrocyte 1:500  Sternberger 
Monoclonals 
Incorporated, USA 
Mouse anti-TGF-bRII TGFb-signaling 1:50 1:100 Santa Cruz, USA 
Rabbit anti-TGF-bRI TGFb-signaling 1:50 1:1000 Santa Cruz, USA 
Rabbit anti- 
pSmad2(Ser465/467) 
TGFb-signaling 1:50 1:1000 Cell Signaling, USA 
Mouse anti Smad2 TGFb-signaling  1:1000 Cell Signaling, USA 
Rabbit anti-
pCREB(Ser133) 
CREB-signaling 1:100 1:1000 Cell Signaling, USA 
Rabbit anti-CREB CREB-signaling  1:1000 Cell Signaling, USA 
Rabbit anti-Actin  Loading control  1:5000 Sigma, Germany 
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3.1.7. Secondary antibodies  
List of Antibodies Dilution  Source  
Donkey anti-rabbit-HRP  1:10000 Dianova, Germany 
Goat anti-mouse  HRP  1:5000 Chemicon,  USA 
Donkey anti-rat- BT 1:500 Jackson Immuno 
Research,USA 
Donkey anti-goat-BT 1:500 Jackson Immuno 
Research,USA  
Donkey anti-rabbit-Alexa 488 1:1000 Molecular Probes, USA 
Donkey anti-goat, Alexa 488 1:500 Molecular Probes, USA 
Donkey anti-mouse- Alexa 488 1:500 Molecular Probes, USA 
Donkey anti-goat, Alexa 568 1:1000 Molecular Probes, USA 
Donkey anti-mouse- RHOX 1:1000 Dianova, Germany 
Donkey anti-rabbit - Alexa 568 1:1000 Molecular Probes, USA 
Donkey anti-mouse- Cy5 1:1000 Jackson Immuno 
Research,USA 
Donkey anti- guinea pig - Cy5 1:500 Jackson Immuno  
Research,USA 
Donkey anti- mouse IgM - Alexa 568 1:500 Molecular Probes, USA 
 
  
3.1.9. Devices 
Device Company 
Tubing pump  Ismatek SA-Switzerland 
Sliding microtome Leica, Solms Diagnostic Instruments, 
USA  
Water bath  GFL,Germany 
Slide Moat Boekel Scientific,USA 
Orbital Shaker colonial scientific, USA 
Weighing Balances Sartorius, Gottingen 
Stereology Stereoinvestigator, MicroBrightField, 
Colchester, USA 
Fluorescence Microscope Leica DMR 
with SPOT  Camera 
Leica, Wetzlar, Germany 
Confocal scanning laser microscope Leica TCS-NT, Wetzlar, Germany 
Inverse Fluorescence microscope 
Olympus IX 70 with Color View 
documentation system 
Olympus, Hamburg 
Soft Imaging Systems, Münster 
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3.1.10. Software 
Adobe Photoshop C2 Version 9.0 Adobe Systems GmbH, München 
Adobe Photoshop element 5 Adobe Systems GmbH, München 
EndNote 10 Thompson ResearchSoft, USA 
GraphPad Prism 5 GraphPad Software Inc., USA 
Microsoft Office Microsoft Corporation 
Spot Advanced for Mac OS Diagnostic Instruments, USA 
analySIS® 3.2  Soft Imaging Systems, Münster, Germany 
Light microscope Olympus CK 30 Olympus, Hamburg 
Photometer Ultrospec 2000 Amersham/Pharmacia Biotech, 
Freiburg 
Centrifuge 5417 R Eppendorf, Hamburg 
Megafuge 1.0 R Heraeus Instruments GmbH, 
Germany 
Emax Precision Microplate Reader Molecular Devices, Union City, CA, 
USA 
Incubator HERA Cell Heraeus, Germany 
Hera Safe cell culture hood Heraeus, Germany 
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3.2. Methods 
 
3.2.1. Animals  
 Two to three months old healthy female Fischer-344 rats (N=5) obtained from 
Charles River were kept under a normal light-dark cycle of 12 hours and had free 
access to food and water.  Eight and 12 months old rats (male) were obtained from a 
colony of tgHD and WT littermates that has been established at the central animal 
facility of the University of Hannover, Germany135. For experiments, offspring derived 
from generation F10 were used. Presence of the huntingtin transgene in tgHD rats 
was confirmed by tail-DNA genotyping at the age of 3 weeks. The brains from 
transgenic mice with inducible neuron-specific expression of TGF-beta1 
(tTACamKIIa/tTA-responsive promoter (Ptet) TGF-beta1)148 were obtained from the 
Department of Neuroanatomy, University of Leipzig, Germany. Induction of TGF-
beta1 expression in these animals was achieved by omitting doxycycline from the 
drinking water for 54 days (TGF-beta1-on mice; N=4 and TGF-beta1-off mice; N=4). 
Tissues from R6/2 mice149 and from TGF-beta infused rats 82 were also used in the 
present study. All experiments were carried out in accordance with the European 
Communities Council Directive of 24 November 1986 (86/609/EEC) and were 
approved by the local governmental commission for animal health. 
 
3.2.2. Intracerebroventricular infusions of TGF-beta1  
 Two to three months old (180 g) female Fischer-344 rats (n=16) received 
intracerebroventricular infusions via stainless steel canules connected to osmotic 
minipumps (Model 2002, ALZET, Durect Corp., Cupertino, USA) as described82.  
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Rats received either recombinant TGF-beta1 (500 ng/ml present in the pump) 
dissolved in artificial cerebrospinal fluid (aCSF) or aCSF as control (n=8 each) at a 
flow rate of 0.5 µl/hr for a period of 14 days. During the last four days of the pump 
period, rats received daily intraperitoneal injections of 50 mg/kg BrdU. Then, rats 
were intracardially perfused with 4% paraformaldehyde.  
 
3.2.3. BrdU labelling 
 Labelling of dividing cells was performed by intraperitoneal injection of the 
thymidine analogue BrdU (5-bromo-2-deoxyuridine) (Sigma, Steinheim, Germany) at 
50 mg/kg of body weight using a sterile solution of 10 mg/ml of BrdU dissolved in a 
0.9% (w/v) NaCl solution. For proliferation studies, animals received two BrdU 
injections with an interval of 12 h and were sacrificed 24 hours after the second BrdU 
pulse. To address cell survival BrdU injections were performed daily on 5 
consecutive days (day 1 to 5) and the animals were sacrificed at day 30.  
 
3.2.4. Tissue processing and Immunohistrochemistry 
 Rats or mice were deeply anesthetized using a ketamine (20.38 mg/ml), 
xylazine (5.38 mg/ml) and acepromazine (0.29 mg/ml) mixture. Transcardial 
perfusion was performed with 0.9% (w/v) NaCl solution followed by a 4% 
paraformaldehyde, 0.1 M sodium phosphate solution (pH 7.4). Brains were removed 
and post-fixed in paraformaldehyde overnight at 4 °C. Tissue was then cryoprotected 
in 30% (w/v) sucrose, 0.1 M sodium phosphate solution (pH 7.4). Brains were cut 
into 40 µm sagittal sections using a sliding microtome on dry ice. Sections were 
stored at - 20 °C in cryoprotectant solution (ethylene glycol, glycerol, 0.1 M 
phosphate buffer pH 7.4, 1:1:2 by volume). Free-floating sections were treated with 
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0.6% H2O2 in Tris-buffered saline (TBS: 0.15 M NaCl, 0.1 M Tris–HCl, pH 7.5) for 30 
min. For immunohistological detection of the incorporated BrdU, pre-treatment of 
tissues was performed as described previously150. Following extensive washes in 
TBS, sections were blocked with a solution composed of TBS, Triton X 100, 0.1%, 
bovine serum albumin 1%, and teleostean gelatine (Sigma, Taufkirchen, Germany) 
0.2% for 1 h. This buffer was also used during the incubation with antibodies. 
Primary antibodies were applied overnight at 4°C. For chromogenic 
immunodetection, sections were washed extensively and further incubated with 
biotin-conjugated species-specific secondary antibodies followed by a peroxidase–
avidin complex solution from the Vectastain Elite ABC kit (Vector Laboratories, 
Burlingame, USA). The peroxidase activity of immune complexes was revealed with 
a solution of TBS containing 0.25 mg/ml 3, 3′-diaminobenzidine (DAB) (Vector 
Laboratories, Burlingame, USA), 0.01% (v/v) H2O2, and 0.04% (w/v) NiCl2. Sections 
were put on Superfrost Plus slides (Menzel, Braunschweig, Germany) and mounted 
in Neo-Mount (Merck, Darmstadt, Germany). For epifluorescence immunodetection, 
sections were washed extensively and incubated with fluorochrome-conjugated 
species-specific secondary antibodies for overnight at 4°C. Sections were put on 
slides and mounted in Prolong Antifade kit (Molecular Probes, Eugene, USA). 
Photodocumentation was done using a Leica microscope (Leica, Wetzlar, Germany) 
equipped with a Spot™ digital camera (Diagnostic Instrument Inc, Sterling Heights, 
USA) and epifluorescence observation was performed on a confocal scanning laser 
microscope (Leica TCS-NT, Wetzlar, Germany). 
 The following antibodies and final dilutions were used. Primary antibodies: rat 
anti-BrdU 1:500 (Oxford Biotechnology, Oxford, UK), mouse anti-PCNA (Proliferating 
Cell Nuclear Antigen) 1:500, goat anti-DCX (Doublecortin) (C-18) 1:500 (both from 
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Santa Cruz Labs, Santa Cruz, USA), mouse anti-NeuN (neuronal nuclei) 1:500 
(Chemicon, Temecula, USA), rabbit anti-GFAP (Glial Fibrillary Acidic Protein) 1:1000 
(Dako, Denmark), rabbit anti-pSmad2 (Phospho-Smad2 (Ser465/467) 1:50 (Cell 
Signaling, Denver, USA), goat anti- Sox2 1:500 (Santa Cruz Labs, Santa Cruz, 
USA). The Secondary antibodies: donkey anti-goat, -mouse, -rabbit or -rat 
conjugated with Alexa 488 (1:1000, Molecular Probes, Eugene, USA), rhodamine X 
(Dianova, Hamburg, Germany), Cy5 or biotin 1:500 (Jackson Immuno Research, 
West Grove, USA). 
 
3.2.5. Counting procedures 
 All morphological analyses were performed on blind-coded slides. Every sixth 
section (240-µm interval) of one hemisphere was selected from each animal and 
processed for immunohistochemistry. To analyze cell proliferation in the dentate 
gyrus (DG) (experiment I), BrdU and PCNA immunopositive cells were counted. To 
assess cell survival in DG (experiment II) BrdU immunopositive cells were quantified. 
To investigate neurogenesis, the number of neural precursor cells ever 12th section 
(480 µm interval) stained for DCX was determined. All cells that were stained by 
BrdU, PCNA or DCX antibodies were counted with 400 x magnification on a light 
microscope (Leica, Wetzlar, Germany) and multiplied by 6 or 12 to obtain an 
estimate of the total immunopositive cell numbers. The reference volume was 
determined by tracing the granule cell layer of the hippocampal DG using a semi-
automatic stereology system (Stereoinvestigator, MicroBrightField, Colchester, 
USA). The total number of neurons in DG was determined in every 12th section 
(480µm intervals) stained for NeuN.  Positive cells for NeuN in the granule cell layer 
of the dorsal hippocampal dentate gyrus were analysed. A systematic counting 
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procedure, similar to the optical dissector  described by Gundersen et al.,151 and 
Williams & Rakic (1988)152. NeuN positive cells were counted within a 15 x 15 µm 
counting frame that was spaced in a 150 x 150 µm counting grid. Granule cell nuclei 
intersecting the uppermost focal plane (exclusion plane) and those intersecting the 
exclusion boundaries of the counting frame were not counted.  The sample volume 
of NeuN positive cells was determined by multiplication of number of frame counted 
x size of the counting frame x thickness of the section. Volume of the entire structure 
is derived by multiplying the reference volume with serious of sections. To obtain the 
neuronal density the total number of cells counted is divided sample volume and 
represented as cells/mm3. All extrapolations were calculated for one hippocampus 
and should be doubled to represent the total hippocampal values. We noticed that 
BrdU positive cells appeared often in clusters, which can be considered as 
proliferating units153. To analyze proliferating units, size of clusters (> 3 cells) in µm2 
and number of BrdU cells per clusters (proliferating units) were quantified on a 
Olympus microscope (Olympus, Hamburg, Germany) using analySIS® 3.2 software 
(Soft Imaging Systems, Münster, Germany). For the analysis of mitotic neuronal 
precursor cells, the BrdU/DCX double positive cells were analysed in BrdU positive 
cell clusters 24 h after BrdU injection.  
 To determine the frequency of neuronal differentiation and cell fate of 
newborn cells (experiment II), a series of every sixth brain section (240-µm interval) 
was stained and analyzed for BrdU/NeuN/GFAP by triple immunofluorescence. 
Undifferentiated, self-renewing and quiescent cells were identified by 
BrdU/Sox2/PCNA triple immunofluorescence. TGF-beta1 signaling was identified by 
presence of pSmad2 in GFAP+/Sox2+ and in DCX+/NeuN+ cells. Neuronal 
differentiation was analyzed by BrdU/NeuN double-stainings, astroglial fate was 
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identified by BrdU/GFAP double-labelling. Stainings were examined using a Leica 
TCS-NT confocal laser microscope (Leica Microsystems, Bensheim, Germany) 
equipped with a 40× PL APO oil objective (1.25 numeric aperture) and a pinhole 
setting that corresponded to a focal plane of 2 µm or less. Due to the relatively high 
age of the animals and the overall low level of neurogenesis, every BrdU labelled cell 
was examined in the cell fate analysis. For the determination of TGF-beta1 signaling 
in neural stem cells or neurons, 50 Sox2 or Sox2/GFAP double positive cells or DCX 
(immature) or DCX (mature) or NeuN positive cells were examined for pSmad2 co-
localization.  
 
3.2.6. Western Blotting 
 Different brain regions from WT or HD rats, or neurospheres were lysed in 
buffer (0.7% NP40, 50 mM Tris-HCl (pH 8.0), 0.1 mM EDTA (pH 8.0), 250 mM NaCl, 
10% glycerol, 0.2 mM Na3VO4, 1 mM PMSF, 10 mM DTT, 2µg/ml Aprotinin and 
1µg/ml Pepstatin) and centrifuged at 17900 xg for 15 min at 4 °C. The protein 
concentration was determined using BCA test (Sigma, Taufkirchen, Germany) the 
resulting supernatants (20 ug of total protein) were size-separated by 12% SDS-
PAGE and transferred onto nitrocellulose membrane (Schleicher and Schuell, 
Dassel, Germany) by semidry electroblot method (Biometra Fast blot, Biometra 
Biomedizinische Analytik, Göttingen, Germany). To determine the endogenous level 
of TGF-beta1 signaling in the rat brain, antibodies used for Western blot and their 
dilutions were as follows: rabbit anti-phospho Smad2  (Ser465/467) 1:1000 and 
mouse anti-Smad2 1:1000 (Both from Cell Signaling, USA); mouse anti-TGFbRII, 
1:500; Rabbit anti-TGFbR1, 1:1000 (Both from Santa Cruz Biotechnology, USA); 
Rabbit anti-Actin 1:5000 (Sigma, Germany). Level of CREB signaling was detected 
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by using rabbit anti-phospho CREB1 (Ser133) 1:1000 and rabbit anti-CREB 1:1000 
(Both from Cell Signaling, USA), rabbit anti-Actin 1:5000 (Sigma, Taufkirchen, 
Germany). Secondary goat anti-mouse 1:5000 (Chemicon, Temecula, USA) or anti-
rabbit IgG-HRP antibodies 1:10,000 (Dianova, Hamburg, Germany) and detection 
was performed using the ECL plus chemiluminescence system (Amersham 
Pharmacia, Freiburg, Germany) and exposed to Hyperfilm (AmershamPharmacia, 
Freiburg, Germany).  
 
3.2.7. Neural stem and progenitor cells culture  
 Adult hippocampal progenitor cells were isolated and cultured as described 
before154. Briefly, two to four month-old female Fischer-344 rats (Charles River 
Deutschland GmbH, Germany) were decapitated and hippocampi were dissected. 
The tissue was homogenized and cells were resuspended in Neurobasal (NB) 
medium (Gibco BRL, Germany) containing B27 supplement (Gibco BRL, Germany), 
2 mM L-glutamine (PAN, Germany), 100 U/ml penicillin / 100µg/ml streptomycin 
(PAN, Germany). For expansion, the NB/B27 was growth factor-supplemented with 2 
mg/ml heparin (Sigma, Germany), 20 ng/ml FGF-2 (R&D Systems, Germany) and 20 
ng/ml EGF (R&D Systems, Germany) (proliferation medium). The cell suspension 
from hippocampi of 5 rats was seeded into a T25 flask (TPP, Switzerland) in 5 mL 
proliferation medium. The cultures were maintained at 37°C in a humidified incubator 
with 5% CO2 and half of the media was changed every 3 to 4 days. For passaging, 
cells were dissociated by using accutase (PAA, Austria) and a total of 5 x 105 cells 
were seeded in a T75 flask (TPP, Switzerland). Neurosphere cultures from passages 
3-7 were used for the experiments.  
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3.2.8. Cell cycle analysis 
 The cell cycle was analyzed by fluorescence activated cell sorting (FACS) 
using a modified Ki67/PI staining protocol from Endl and colleagues155. Neural 
progenitors derived from adult rat hippocampus were seeded into T25 flasks (TPP, 
Switzerland) and stimulated with 10 ng/ml TGF-beta1 or PBS control for 7 days. 
TGF-beta1 was added every second day. On day 7, cells were spun down, medium 
was removed and cells were fixed with 1 ml ice cold 70% EtOH. After fixation cells 
were washed with ice cold PBS and then resuspended in 500 µl ice cold PBS 
containing 0.1% TritonX-100 and incubated for 5 min on ice. After two subsequent 
washing steps, cells were resuspended in 100 µl of a 1:6 dilution of the antibodies in 
PBS (100 µl PBS + 20 µl antibody IgG or Ki67; BD Biosciences Pharmingen, FITC 
conjugated antibodies). After 30-40 min incubation at 4°C, cells were washed with 1 
ml PBS and then resuspended in PBS for staining. In case of PI staining, cells were 
resuspended in 470 µl PBS. Cells without PI staining were resuspended in 495 µl. All 
samples were treated with 5 µl of RNase for 1 hour to eliminate the RNA, which 
would interfere with the PI staining. After this 1h incubation at 37°C, 25 µl of PI were 
added to the respective samples. The stained cells were analyzed with the Flow 
Cytometer (FACS Calibur, Becton Dickinson, Heidelberg). Data was analyzed using 
Win MDI 2.8 software.  
 
3.2.9. Immunocytochemistry 
 Fixed cells were washed in TBS (0.15 M NaCl, 0.1 M Tris-HCl, pH 7.5), then 
blocked with solution composed of TBS; 0.1% Triton-X100 (only for intracellular 
antigens); 1% bovine serum albumin (BSA) and 0.2% Teleostean gelatin (Sigma, 
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Taufkirchen, Germany) (Fish Skin Gelatine Buffer, FSGB). The same solution was 
used during the incubations with antibodies. Primary antibodies were applied 
overnight at 4°C. Fluorochrome-conjugated species-specific secondary antibodies 
were used for immunodetection. The following antibodies and final dilutions were 
used. Primary antibodies: rabbit guinea pig anti-GFAP 1:1000 (Progene, Germany); 
IgM mouse anti-A2B5 1:200 (Chemicon, UK); mouse anti-rat nestin 1:500 
(Pharmingen, U.S.A.); mouse anti-Map 2a+2b 1:250 (Sigma, Germany); mouse anti-
Myelin Basic Protein (MBP) 1:750 (SMI-94, Sternberger Monoclonals Incorporated, 
U.S.A.). Secondary antibodies: donkey ant-mouse, rabbit conjugated with Alexa 
Fluor 488 (Molecular Probes, U.S.A.), rhodamine X (RHOX) 1:1000 (Dianova, 
Germany). In cases of detergent-sensitive antigens (i.e., A2B5), Triton X-100 was 
omitted from FSGB buffer. Nuclear counterstaining was performed with 4´, 6´-
diamidino-2-phenylindole dihydrochloride hydrate at 0.25 µg/µl (DAPI; Sigma, 
Germany). Specimens were mounted on microscope slides using in Prolong Antifade 
kit (Molecular Probes, U.S.A.). Epifluorescence observation and photo-
documentation were realized using a Leica microscope (Leica Mikroskopie und 
Systeme GmbH, Germany) equipped with a Spot™ digital camera (Diagnostic 
Instrument Inc, U.S.A.).  
 
3.3. Statistical Analysis 
 The data are presented as mean values ±SD. Two-way analysis of variance 
(groups ± age) and Bonferroni post test (tgHD rats) or Student t-test (TGF-beta- on 
mice) were used for analyzing numbers of PCNA-positive and BrdU-positive cells, 
numbers of BrdU clusters, numbers of BrdU-positive cells per clusters, sizes of BrdU 
clusters, total DCX-positive cells, total neuronal number and neuronal density, and 
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percentage of BrdU/NeuN, BrdU/NeuN/GFAP- and BrdU/Sox2/PCNA-positive cells. 
One-way analysis of variance test was used for percentage of Sox2/GFAP/pSmad2-
positive cells, and a Tukey test comparison was performed for post hoc analysis. 
Student t-test was applied for analyzing the number of PCNA-positive cells in R6/2 
mice, percentage of BrdU/ DCX double-positive cells in tgHD and WT rats, numbers 
of BrdU-positive cells in the TGF-beta1 infusion study, and for cell cycle phase 
analysis. Statistical analysis was performed using Prism (Prism GraphPad Software, 
San Diego, CA). The significance level was at p G 0.05, unless otherwise indicated. 
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4. Results  
4.1. TGF-beta1 signaling components are expressed throughout the adult rat 
brain.  
 TGF-b receptor II, receptor I, and Smad2 are integral downstream 
constituents of the TGF-beta1 signaling cascade. Typically, ligand binding and TGF-
beta receptor activation triggers phosphorylation of Smad2, and phospho-Smad2 is 
widely used as a marker indicating a TGF-beta signaling response 65. Here, we 
investigated protein expression of TGF-bRII, TGF-bRI, Smad2 and phosphorylation 
of Smad2 in the hippocampus (HC), ventricle wall including the sub-ventricular zone 
(SVZ), olfactory bulb (OB), cortex (Cor) and cerebellum (CB) by Western blot 
analysis; lung tissue was used as control (Fig 4.1). TGF-betaRII and RI were 
detected in all brain regions with the neurogenic regions HC and SVZ showing the 
least expression. The highest expression of TGF-betaRII was found in the lung. In 
contrast to that, the downstream signaling molecule Smad2 was strongly expressed 
in the different brain regions and only faintly detected in the lung. More importantly, 
while in lung tissue Smad2 was apparently in its non-phosphorylated and therefore 
inactive state, it was phosphorylated in the brain. This suggests that TGF-beta 
signaling is active in various regions of the adult rat brain including the neurogenic 
regions (Fig 4.1). 
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Fig.4.1. Westernblot analysis demonstrating TGF-beta1 signaling components 
in intact adult brain. Note the expressions of TGF-betaRII, TGF-betaRI and 
phosphorylated form of Smad2 in different brain regions. B-Brain, HC-Hippocampus, 
SVZ-Sub ventricular Zone, OB-Olfactory bulb, Cor-Cortex, CB-Cerebellum and non-
neuronal tissue- Lung. Smad2 and Actin as controls. 
                                     
 
In order to substantiate the TGF-beta signaling profiling, we performed an extensive 
semiquantitative immunohistochemical analysis of the TGF-beta signaling 
components in different brain regions. Overall, we encountered a low 
immunoreactivity of TGF-betaRII in the adult rat brain (Table1 and Fig 4.2). Faint 
perinuclear signaling was present in cells of the CA1 and CA2 regions of 
hippocampus, in the cerebral cortex cortex, in Purkinje cells of the cerebellum and 
cells of the brain stem (Table 1). Within the neurogenic regions TGF-betaRII 
immunoreactivity was faint (Table 1, Fig 4.2). In contrast to the weak TGF-betaRII 
immunoreactivity, a robust staining for TGF-betaRI was noticed in the HC, in the 
rostral migratory stream (RMS) and in the OB. In the stem cell niche, expression of 
TGF-betaRI was clearly visualized in the SGZ of HC and in the SVZ. In addition, 
expression of TGF-betaRI was found in cells of the striatum, Cor, CB and in the brain 
stem (Table 1 and Fig 4.3). A prevalent expression of pSmad2 was observed in most 
brain regions (Table 1 and Fig 4.4). For example, pSmad2 immunoreactivity was 
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prominent in the Cor, Strr, CB and in the brain stem, in the CA1, CA2 and CA3 
regions of HC, in the SVZ, along the RMS and in the OB.  
 
 
 
                              
Fig.4.2. Localization of TGF-betaRII (green) immunoreactivity in different areas 
of the intact adult rat brain. Note the expression of TGF-betaRII in the DG-Dentate 
Gyrus, in the SVZ-Subventrivular Zone, in the OB-Olfactory bulb and in the Cor-
Cortex. scale bar, 50µm. Insets are higher magnifications of selected fields. 
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Fig.4.3. Localization of TGF-betaRI immunoreactivity in different areas of intact 
adult rat brain. Note the widespread expression of TGF-betaRI in the DG-Dentate 
Gyrus, in the SVZ-Subventrivular Zone, in the OB-Olfactory bulb, in the Str-Striatum, 
in the Cor-Cortex, in the CB-Cerebellum and in the B Stem-brain stem. scale bar, 
100 µm. Insets are higher magnifications of selected fields. 
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Fig.4.4. Localization of pSmad2 immunoreactivity in different areas of intact 
adult rat brain. Note the phosphorylated form of pSmad2 expression in the DG-
Dentate Gyrus, SVZ-Subventrivular Zone, OB-Olfactory bulb, Str-Striatum, Cor-
Cortex, CB-Cerebellum and B Stem-brain stem. However, it is highly limited in stem 
cell niche, SGZ of DG and SVZ. scale bar, 100µm. Insets are higher magnifications 
of selected fields. 
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4.2. Table 1 
Semiquantitative measurement of immunoreactivity of TGF-betaRII, 
TGF-betaRI and pSmad2 in the adult rat brain   
Brain Area TGF-betaRII TGF-betaRI pSmad2 
TELENCEPHALON 
Olfactory system 
Glomerular cell layer ++ ++++ ++ 
Granule cell layer + ++++ ++++ 
Neocortex 
Ventrolateral orbital cortex ++ ++++ +++ 
Frontal cortex +++ ++++ +++ 
Parietal cortex + ++++ +++ 
Occipital cortex ++ ++++ ++++ 
Entorhinal cortex +++ +++ ++++ 
Metacortex 
Cingulate/retrosplenial cortex + +++ ++++ 
Hippocampal formation 
Dentate gyrus(GCL) + ++ +++ 
Hilus dentate gyrus <+ +++ + 
CA1 region ++ +++ +++ 
CA2 region <++ +++ +++ 
CA3 region + +++ +++ 
Hippocampal fissure + ++ - 
Subiculum + ++ ++ 
Fimbria of hippocampus ++ ++ - 
Basal ganglia 
Striatum ++ ++++ +++ 
Globus palidus + ++++ + 
Nucleus accumbens ++ ++ + 
Amygdala 
Central amygdaloid nucleus ++ +++ + 
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Table.1. Each brain region was evaluated for the relative density of TGFbetaRII, 
TGFbetaRI or pSamd2 immunostaining. (–) no stained cells observed, (+) only few 
Medial amygdaloid nucleus <+ ++ + 
DIENCEPHALON    
Thalamus + +++ + 
Hypothalamus ++ ++++ +++ 
MESENCEPHALON    
Substantia nigra pars 
compacta 
+ ++ ++ 
Substantia nigra pars 
reticulate 
++ ++ +++ 
Subthalamic nucleus  <+ +++ + 
Ventral tegmantal area <+ +++ + 
Red nucleus +++ +++ ++ 
Superior colliculus <+ +++ ++ 
Inferior colliculus <+ +++ ++ 
METENCEPHALON     
Pons ++ ++ ++ 
Cerebellum    
Granular cell layer + ++++ + 
Purkinje cell layer ++ +++ ++++ 
Deep cerebellar nuclei <++ +++ ++++ 
Molecular layer ++ + + 
White matter ++ + - 
Nonneuronal cells    
Choroid plexus +++ (++++) + 
Ependymal cells <+ ++++ +++ 
Neurogenic areas    
Subventricular zone <+ ++++ + 
Subgranular zone + +++ + 
Rostral Migratory 
Stream(RMS) 
<+ ++++ ++ 
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cells stained, (++) sparse staining (stained cells in < 25% field), (+++) strong staining 
(stained cells in <50% field), (++++) robust staining (stained cells/fibers in >50% 
field). 
 
 
4.3. pSmad2 is predominantly present in postmitotic cell in the hippocampus 
of  the adult rat brain 
 For a more detailed investigation on the expression of pSmad2 in the 
hippocampal neurogenic niche we analyzed neural stem cells (radial GFAP and/or 
Sox2 expressing cells), young  immature neurons (DCX expressing cells), and 
mature neurons (NeuN positive cells) for the presence of pSmad2 immunoreactivity. 
Most of the GFAP positive cells within the SGZ (77.4 ± 4.1%) were negative for 
pSmad2 immunoreactivity (Fig 4.5). Likewise, the majority of GFAP/Sox2 double 
positive cells (62±2%) in the SGZ failed to co-localize with pSmad2 (Fig 4.5). 
Approximately half of the Sox2 expressing population (48.6±4.1%) stained for 
pSmad2. The DCX population was subdivided according to their dendritic 
morphology150 into immature (short horizontal processes) and mature (perpendicular 
dendritic arborization into the molecular layer) DCX positive cells150. Here, 37.5±7.8 
% of DCX cells with an immature morphology, and 79.3±5% of DCX-expressing cells 
presenting a mature morphology showed a positive pSmad2 staining (Fig 4.5). 
Virtually all (96±2%) NeuN expressing cells stained for pSmad2 (Fig 4.5). The 
summary of these data is presented in figure 4.5F. Overall, the expression pattern of 
pSmad2 in the hippocampal neural stem cell niche suggests that TGF-beta signaling 
is active primarily in cells with neuronal commitment and/or neuronal identity. 
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Fig.4.5. Expression of pSmad2 (green) in stem cell niche of the intact adult rat 
brain.  
A) Absence of pSmad2 (green) in GFAP positive (blue) in SGZ.B) Co-localization of 
pSmad2 (green) in Sox2 (red) positive cells but not in all Sox2 positive cells in SGZ. 
C) Appearance of pSmad2 (green) in DCX cells of the hipocamapal DG . D) Solid 
co-localization of pSmad2 (green) in NeuN (red) positive neurons in the GCL. scale 
bar, 50 µm. Insets are higher magnifications of the selected fields. E) Quantitative 
analysis of GFAP, Sox2, Sox2/GFAP double, DCX and NeuN labelled cells that are 
positive for pSmad2. Note the gradual increase of percentage of cell from stem cells 
towards neurons that co labelled with pSmad2. F) Schematic summary of pSmad2 
expression (green) in neurogenesis at different cellular level in Hippocampal DG. 
Expression of pSmad2 (green) is prominent in NeuN positive cells (gray cells) and 
certain amount of DCX expressing cells (red). However, it is absent or low in the 
GFAP and Sox2 expressing stem cells (blue) in SGZ. 
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 In a parallel study, we noticed that approximately 25% of the BrdU label 
retaining cells in the hippocampal stem cell niche were Sox2 positive and quiescent, 
i.e. PCNA negative. Moreover, a minor population of label retaining cells were Sox2 
and PCNA positive (less than 5%). This, together with the present findings on 
pSmad2 positive as well as negative subpopulations of Sox2 and GFAP expressing 
cells provokes the possibility that stem cell quiescence might be regulated through 
pathways involving Smad2 signaling. Also, since i) the young immature DCX 
population of cells is in cell cycle and the mature DCX positive cells are postmitotic ii) 
pSmad2 in DCX positive cells is found primarily in the mature population, we 
hypothesized that cell cycle exit in the DCX population might involve Smad2 
signaling. Therefore, we analyzed Sox2, GFAP and also DCX expressing cells in the 
hippocampal stem cell niche for the presence or absence of pSmad2 and/or PCNA. 
In most of the cases, PCNA and pSmad2 were virtually exclusive. Sox2 positive cells 
in the SGZ, which were pSmad2 positive, did never label for PCNA and vice versa 
(Fig 4.6). The vast majority of GFAP positive cells failed to stain for pSmad2 .  The 
immature DCX population was pSmad2 negative but positive for PCNA (Fig 4.6). In 
summary, while proliferating progenitors and neural stem cells are mostly devoid of 
any detectable pSmad2, it appears that cells become pSmad2 positive while they 
exit the cell cycle to either progress along the neuronal determination, differentiation 
and maturation program or to enter a quiescent neural stem cell stage.   
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Fig.4.6. TGF-beta1 signaling is absent in proliferating stem and progenitor 
cells A) Absence of pSmad2(green) in Sox2 (blue)/PCNA (Red) double positive cells 
in the SGZ of the hippocampus but arrow shows co-localization of pSmad2 (green) 
in Sox2 (blue) positive /PCNA negative cell(red). B) Absence of pSmad2 (green) in 
GFAP (blue)/PCNA (Red) double positive cells in the SGZ of the hippocampus. C) 
Absence of pSmad2 (green) in DCX (blue)/PCNA (Red) double positive cells in the 
SGZ of the hippocampus. Insets are higher magnifications of the selected fields . 
 
4.4. Induced over-expression of TGF-beta1 in the hippocampus reduces cell 
proliferation, but promotes neuronal differentiation and survival.   
Wachs et al., had recently demonstrated that a 7 day intracerebroventricular 
infusion of TGF-beta1 reduced cell proliferation in the hippocampus and ventricle 
wall without affecting cell fate82. Based on the stimulatory effects of TGF-beta1 on 
neuronal differentiation, functional maturation and survival presented above, we re-
examined the effects of TGF-beta1 on the neural stem cell niche, however, using an 
animal model that allows the inducible and sustained expression of TGF-beta in the 
hippocampus. This was accomplished using our previously generated transgenic 
mouse model, which expresses TGF-beta1 in the hippocampus under a tetracycline 
regulatable Ca-Calmodulin kinase promoter 148.  
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 First, we confirmed that a 2 months induction of TGF-beta1 elevates the 
levels of pSmad2 in the dentate gyrus. In addition to the overall elevation of the 
staining intensity of pSmad2 in the granule cell layer, the TGF-beta-on mice 
presented strong pSmad2 immunereactivity in Sox2 / GFAP positive cells, compared 
to the TGF-beta-off animals (Fig. 4.7a). Cell proliferation, as determined by the 
number of PCNA positive cells, in the subgranular zone was significantly reduced in 
the TGF-beta-on mice (Fig. 4.7b). The number of young immature neurons, 
however, as determined by counting of DCX positive cells, was not changed (Fig. 
4.7b). Moreover, the number of surving cells 4 weeks after BrdU labelling, was 
increased (Fig. 4.7b). Thus, even though less cells are produced after TGF-beta1 
over-expression, the survival of newly generated cells is dramatically increased 
resulting in a net gain of cells. Even though the percentage of cells acquiring a 
neuronal phenotype (approx. 60%) did not change upon TGF-beta1 over-expression, 
the increased survival of cells results in a net gain of  neurons in the hippocampal 
DG (Fig. 4.7b).  
          
Fig. 4.7a. pSmad2 staining in hippocampal DG of TGF-beta-off and -on mice. 
Note the prominent immunoreactivity of pSmad2 in the hippocampal DG of TGF-beta 
on mice. pSmad2 (green) is strongly present in Sox2 (red)/GFAP (blue) double 
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positive cells specifically in the SGZ of the hippocampus from TGF-beta1-on mice. 
Scale bar, 100 m.  
 
                       
Fig.4.7.b. Reduced proliferation but increased neuronal survival in the 
hippocampus of TGF-beta-on mice  
A-A1) Qunatification of the number of PCNA positive cells in the DG of TGF-beta-off 
and TGF-beta-on mice. Data are expressed as means ± SD. For statistical analysis 
a Student t-test was performed. Note the reduction of PCNA positive cells in TGF-
beta -on mice (A1*p<0.05). B-B1) Qunatification of the number of DCX positive cells 
in the DG of TGF-beta-off mice and TGF-beta-on mice and result are not significant 
(B1). C-C1) Qunatification of the number of BrdU positive cells (from 4 weeks of 
survival experiment) in the DG of TGF-beta-off mice and TGF-beta-on mice. Note 
the increment of BrdU positive cells in TGFbeta-on mice (C1**p<0.01). D-D2) 
Qunatification of the phenotype of BrdU positive cells. Note the increased total 
number of BrdU/NeuN doublpositive neurons in the DG of TGF-beta-on mice 
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(D2*p<0.05). Scale bar, 50 m. Insets are higher magnifications of the selected 
fields. 
 
 
4.5. Elevated levels of TGF-beta1 provokes expression of pSmad2 in neural 
stem and progenitor cells. 
 TGF-beta signaling seems to be absent or low in the proliferating neural 
progenitor cell population, while in neighboring quiescent stem cells and neurons the 
TGF-beta signal cascade is on. Thus, we wanted to know, if a TGF-beta response 
can be triggered in the neural stem and progenitor population by elevated levels of 
TGF-beta1.  In vitro, expression of TGF-betaRII, TGF-betaRI and pSmad2 was 
evaluated by Western blot analysis and by immunofluorescence stainings.  
 TGF-betaRI and Smad2 were clearly detected in control as well as in TGF-
beta1-stimulated neurosphere homogenates (Fig 4.8). TGF-betaRII was weakly 
present in control cultures, however, elevated a fter TGF-beta1 stimulation with a 
maximum expression level at 2 hrs after treatment (Fig 4.8). pSmad2 was below the 
level of detection in control neuro-sphere homogenates, but induced after TGF-beta1 
stimulation with a peak level of phosphorylation at 2 hrs after stimulation (Fig 4.8). 
Since neurosphere cultures consist of a heterogeneous cell population with stem 
cells, progenitors and determined cells present in the cultures, we analyzed the 
identity of neurosphere-derived cells that respond to TGF-beta1 with an induction of 
a pSmad2 signal under proliferation conditions, i.e. in the presence of EGF and FGF-
2. While GFAP positive, Nestin positive and A2B5 positive cells (Fig 4.9) were 
virtually devoid of any detectable pSmad2 signal in the control conditions, TGF-beta1 
induced the appearance of a nuclear pSmad2 signal 90 min after TGF-beta1 
stimulation indicating that neural stem and progenitors are responsive to TGF-beta1 
(Fig 4.9). As one of the biological consequences of TGF-beta1 signaling in 
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neurosphere cultures, we recently demonstrated that TGF-beta1 stimulation inhibits 
progenitor proliferation 82. 
 
 
 
 
                                                           
 
Fig.4.8. Western blot analysis demonstrating the kinetic regulation of TGF-
beta1 signaling in stem and progenitor cells in vitro. Note the trace amount of 
expressions of TGF-beta RII in NSC-NPCs, it is slightly up regulated at 80 mins and 
2hr upon TGF-beta1 stimulation while expression of TGF-bRI showed a steady state 
level. However, Smad2 is not phosphorylated in NSC-NPC, but it peaked at 80 mins 
and 2 hrs upon TGF-beta1 stimulation. Even though it is tent to baseline, 
phosphorylation of pSmad2 is detectable after 12 hrs that show its long lasting 
capacity. 
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Fig.4.9. Immunostaning of pSmad2 in stem cell and progenitor cells in vitro 
with or without TGF-beta1 treatment. A) Note the  translocation of pSmad2 
(green) into nucleus (blue-DAPI) A) of GFAP positive cells(red), B) of Nestin positive 
cells(red) and C) of A2B5 cells (red) in TGF-beta1 treatment, while control condition 
show a trace amount of pSmad2 expression. Scale bar, 50 µm. Insets are higher 
magnifications of arrowed fields. 
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 Finally, we used neurosphere derived cells that were differentiated using 
growth factor withdrawal and addition of serum and analyzed astroglial (GFAP 
positive), oligodendroglial (MBP positive) and neuronal (Map2ab positive) cells for 
their responsiveness to TGF-beta1. A 90 min stimulation with TGF-beta1 induced an 
elevation and translocation of pSmad2 into the nucleus of GFAP positive, MBP 
positive and Map2ab positive (Fig 4.10) cells indicating that all three cell lineages of 
the CNS are responsive to TGF-beta1. We also noticed a reduction in the MBP 
signal in the TGF-beta1 stimulated cultures. This confirms own data demonstrating a 
significant reduction of MBP mRNA expression in neurospheres after TGF-beta 
stimulation in a whole genome expression profiling (data not shown).  
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Fig.4.10. Immunostaning of pSmad2 in matured cell populations of the CNS at 
invitro status with or without TGF-beta1 treatment. Note the  translocation of 
pSmad2 (green) into nucleus (blue-DAPI) A) of GFAP positive astrocytes (red), B) of 
MBP positive oligodendrocytes (red) and C) of MAP2ab positive neurons (red) in 
TGF-beta1 treatment, while control condition show a basal amount pSmad2 
expression. Note the down regulation of MBP expression in oligodendroctes in TGF-
beta1 treatment.  Scale bar, 50 µm. Insets are higher magnifications of nucleus of 
the cells, pSmad2(green) DAPI(blue). 
 
 
4.6. Regulation of hippocampal neurogenesis in tgHD rats 
 Cognitive impairment is a prominent manifestation observed in HD patients, 
as well as animal models of HD74, 132, 156, 157. In the tgHD rat model, working memory 
deficits starts to develop with 9 months and reaches a plateau with 12 months of 
age132. Given that working memory is tightly associated with hippocampal function 
and requires persisting neurogenesis 158-161, we hypothesized that the hippocampal 
stem cell niche in tgHD animals might undergo some fundamental molecular and 
cellular changes affecting neurogenesis.  
 
4.7. Hippocampal cell proliferation in tgHD rats gets progressively impaired 
between 8 and 12 months of age.  
 Neural progenitor‟s proliferation in the dentate gyrus (DG) of tgHD rats and 
WT littermates was analyzed by quantifying the number of BrdU- and of PCNA-
positive cells (Fig. 4.11). Eight months old tgHD rats showed a frequency of BrdU 
incorporation similar to their WT counterpart (WT: 159±78 vs. HD: 179±93) (Fig. 
4.11). In contrast, in 12 months old rats the number of BrdU labelled cells in the DG 
was significantly reduced compared to WT (WT: 88±62 vs. HD: 32±15) (Fig. 4.11). 
Immunohistological analysis of PCNA, a protein expressed throughout the cell cycle, 
confirmed this significant reduction in proliferating cells in 12 months old tgHD rats 
(WT: 99±26 vs. HD: 60±24) (Fig. 4.11). In addition, we also observed the expected 
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age-related decline in progenitor proliferation in WT controls, although it is assumed 
to be not reached the level of statistical significance (Fig. 4.11). 
 
 
                           
Fig.4.11. Impaired hippocampal proliferation in 12 month-old tgHD rats.  
BrdU labelling of 12 month-old WT and tgHD hippocampus (A). Insets are higher 
magnifications of the selected fields. Scale bar, 100 m. Quantitative analysis of 
number of BrdU positive cells in 8 months (B) and 12 months (C) rats 24 h after 
BrdU injections and of PCNA expressing cells in 8 months (D) and 12 months (E) 
rats expressed as positive cells per hippocampus (mean±SD; Student t-test). Note 
that in the 8 months rats there was no difference between WT and tgHD, while in 12 
month-old tgHD the number of BrdU (C) (*p<0.05) and PCNA (E) (*p<0.05) positive 
cells were significantly reduced. N=4 for WT and N=8 for tgHD.  
 
 
4.8. Impaired survival of newly generated cells and reduced neuronal density 
was mediated by reduced CREB signaling in tgHD rat hippocampus.   
 Next, we analyzed survival and fate of newly generated cells in the transgenic 
rats four weeks after proliferating cells were labelled with BrdU (Fig. 4.12). The total 
number of BrdU positive cells was significantly lower in the DG of tgHD rats 
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compared to WT in the 8 months (WT 91.5±41 vs. HD 14.2 ± 23; Fig 4.12) and 12 
months groups (WT 137 ± 82 vs. HD 53 ± 25; Fig 4.12) indicating that survival of 
newly generated cells in the DG of tgHD rats was reduced as compared to WT 
littermates.  
 Signaling via the cAMP responsive element-binding protein (CREB) is known 
to be involved in regulating neuronal survival 162, 163. Thus, we hypothesized that the 
reduced survival of newly generated cells observed in tgHD rats might correlate with 
altered CREB signaling. Western blot analysis demonstrated reduced expression of 
CREB protein in the hippocampi of tgHD rats compared to WT (Fig. 4,12). Moreover, 
the levels of CREB phosphorylation were diminished in tgHD rats (Fig. 4.12D). 
Further evidence that CREB signalling is impaired in HD was provided by our recent 
gene expression profiling of human HD brain revealing a down-regulation of CREB-
regulated transcription co-activator 1 mRNA expression as well as of p300/CBP-
associated factor and of cyclic AMP-regulated phosphoprotein expression71. 
Moreover, difference in proliferation of neural progenitors and cell survival in tgHD 
rat brain might be crucially influenced to total number of existing matured neuron 
population. In order to test that, we analyzed total number of neuron in the 
hipocampal DG of transgenic HD rats by using histological brain sections stained for 
NeuN. The density of total number of NeuN positive cells (cells/mm3) was 
significantly lower in the DG of tgHD rats compared to WT in the 8 months (WT 
4372718±632610.1 vs. HD 3049741±814185; Fig. 4.12) and 12 months groups (WT 
3160326 ± 237335 ± 82 vs. HD 2369196 ± 213716 Fig. 4.12) indicating that total 
number of matured neurons in the DG of tgHD rats was reduced as compared to WT 
littermates. 
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Fig.4.12. Reduced cell survival in tgHD rats is associated with diminished 
CREB signaling.  
A) BrdU labelled cells in the DG 4 weeks after injecting BrdU into 8 month-old WT 
and tgHD rats; scale bar, 50 m. Insets are higher magnifications of the selected 
fields. B) and C), quantitative analysis of BrdU labelled cells 4 weeks after BrdU 
labelling. Note the significant reduction of surviving cells in the tgHD in the 8 months 
(B) (**p<0.001) and 12 months (C) (*p<0.05) (mean±SD; Student t-test). N=4 for WT 
and N=8 for tgHD. D) Western blot analysis demonstrating lower levels of CREB and 
p-CREB in tgHD hippocampi. Actin is used as loading-control. E) and F), quantitative 
analysis of density of NeuN positive cells in the DG. Note the significant reduction of 
neuronal density in the tgHD in the 8 months (E) (*p<0.05) and 12 months (F) 
animals (***p<0.0001). G) and H) quantitative analysis of the total number of neurons 
in the DG. Note the significant reduction in the total number of neurons in the tgHD in 
8 months (G) (**p<0.01) and 12 months (H) animals (***p<0.0001). Data are 
expressed as means ± SD. For statistical analysis a student test was performed. 
N=4 for WT and N=8 for tgHD in E-H. 
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4.9. Increased quiescence of newly generated cells in tgHD dentate gyrus.   
 Four weeks after BrdU labelling, neuronal and astroglial differentiation of 
newly generated cells was analyzed by confocal analysis of BrdU lableld cells 
positive for NeuN (neurons) or GFAP (astroglia) expression (Fig. 4.13). In the DG of 
8 and 12 month-old WT rats, newly generated cells predominantly differentiated into 
neurons (Fig. 4.13). In tgHD rats in contrast, neuronal differentiation was significantly 
reduced (8 months: WT, 77.7±6.6 vs. HD, 30.3±7.9%; 12 months: WT, 76.5±21 vs. 
HD, 43.8±13.6%) (Fig. 4.13). Regardless of the age and the presence of the 
transgene, approximately 10% of newly generated cells differentiated into GFAP-
positive astroglial cell (data not shown). However, there was a striking increase in 
the pool of BrdU-positive cells that did neither co-label with NeuN nor with GFAP (8 
month: WT, 11.9 ± 4 vs. HD, 57.8 ± 16.5%; 12 month: WT, 15.9 ± 4.7 vs. HD, 48.9 ± 
22%). Thus, reduced neuronal differentiation of newly generated cells was 
associated with an increase of cells remaining undifferentiated and/or in a quiescent 
stem cell stage.  
 
 To define the cell identity of BrdU-retaining undifferentiated cells in more 
details, we further analyzed for the presence of Sox2, a marker for functional stem 
cell maintenance and for the presence of the proliferation marker PCNA. As 
compared to WT, tgHD rats contained a strongly increased number of Sox2 positive 
cells in the DG. Moreover, the number of BrdU/Sox2 double positive cells was also 
significantly increased in the tgHD rats (Fig 4.13) (8 months: WT: 25 ± 1.6 vs. HD: 
52.5 ±6.3%; 12 months: WT: 26.3 ± 9.7 vs. HD: 61.62 ± 4%). In both genotypes 
however, the vast majority of BrdU-retaining/Sox2-positive cells found in the SGZ 
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were PCNA negative (Fig. 4.13). Taken together, our observation indicates that the 
number of quiescent stem cells is increased in tgHD hippocampus.  
        
 
Fig.4.13. Deficiency in neuronal differentiation and augmentation of 
quiescence in stem cells in tgHD rats. 
A)  Confocal analysis of BrdU labelled cells (red) that colocalize with NeuN (green) 
or with GFAP (blue) 4 weeks after BrdU injection of a 8 month-old WT rats. Scale bar 
= 50µm. B) and C) Quantitative analysis of BrdU labelled cells that did not co-
localize with a differentiation marker, or that co-localized with NeuN for neuronal 
differentiation 8 month-old (B) and 12 month-old (C) rats. Note the reduction in 
neuronal differentiation that is accompanied with an increase in the number of 
undifferentiated cells (data presented as means±SD; ***p < 0.0001; *p < 0.05; Two-
way analysis of variance-Bonferroni post test). D) Sox2 staining in the DG of WT and 
tgHD rats (12 months). Note the prominent immunoreactivity of Sox2 in tgHD DG; 
scale bar, 100µm. E) Illustration of triple staining of BrdU (green) / Sox2 (red) / 
PCNA (blue) in WT and tgHD DG 4 weeks after BrdU injection (8 Months). Note that 
in WT, BrdU positive cells are negative for Sox2 and for PCNA, while in tgHD brains, 
BrdU labelled cells are positive for Sox2 but negative for PCNA. A control for PCNA 
is included (P). Scale bar = 50µm. F) and G) Quantitative analysis of BrdU labelled 
cells that are positive for Sox2 but negative for PCNA. Note that the percentage of 
BrdU labelled cells that co-labelled with express Sox2 and that are PCNA negative is 
increased in tgHD in 8 months (***p<0.0001) (F) 12 month (***p<0.0001) rats (G). 
There was no significant difference observed in BrdU/Sox2/PCNA triple positive cells 
(F, G). N=4 for WT and N=8 for tgHD.  
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4.10. Neuroblast proliferation compensates stem cell quiescence in tgHD 
dentate gyrus  
 As a consequence of increased stem cell quiescence in tgHD SGZ (Fig. 4.13), 
one could expect total cell proliferation to be diminished. However, in 8 month-old 
tgHD DG, the rate of cell proliferation was unaffected (Fig. 4.11). To elucidate this 
apparent incongruity, we investigated the identity of 8 month-old tgHD DG 
proliferating cells more in details.  
 Twenty-four hours after BrdU injection, BrdU-labelled nuclei were 
predominantly found in cell clusters typically containing a minimum of three and up to 
6 cells in the innermost region of the GCL and in the SGZ (Fig. 4.14). The number of 
such BrdU cell clusters, which can be considered as proliferating units , was 
significantly reduced in the tgHD DG as compared to their WT counterpart (Fig 4.14)  
(8 months: WT: 43.5 ± 13.3 vs. HD: 23.2 ± 10.3; 12 months: WT: 15 ± 6 vs. HD: 4.5 
± 2.7). However, the number of BrdU-labelled cells per unit and, as a consequence, 
the activity of the proliferating units, were significantly elevated in 8 month-old tgHD 
rats, but not in 12 month-old rats (8 months: HD: cluster size 369.4± 166 µm2, 6.6 
cells/cluster; WT: cluster size 115± 115 µm2, 4.2 ±1.2 cells/cluster) (Fig. 4.14). Co-
labelling of BrdU-positive cells in the clusters with the neuroblast marker DCX 
revealed a significant increase in the proportion of DCX-expressing cells in 8 month-
old rats (WT: 47 ± 5 vs. HD: 73 ± 6.6%) (Fig. 4.14). This increase was also reflected 
in the total number of DCX-positive cells that expanded by 237.5% in the DG of tgHD 
rats as compared to WT (Fig. 4.14). Moreover, we could detect DCX-containing 
axons projecting towards the CA3 regions frequently and specifically in the hilus of 8 
month-old tgHD rats (Fig. 4.14). The total number of DCX-expressing cells was 
significantly reduced by 58,7% in the DG of 12 month-old HD rats as compared to 
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their WT littermates (Fig. 4.14). This important reduction resulted most likely from a 
combination of impaired proliferation and reduced survival (Fig. 4.11 and 4.12).  
Thus, despite the elevated numbers of quiescent Sox2-positive stem cells, the 
overall proliferation level in the DG was maintained in the DG of 8 month-old tgHD 
rats through a compensative increased proliferation of the DCX-expressing 
neuroblast population. In the 12 month-old tgHD rats however, the severe 
proliferative and survival deficit could not be rectified anymore.  
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Fig. 4.14. Neuroblast proliferation in 8 month old tgHD hippocampus.  
A) Clusters of BrdU positive cells indicating proliferative units in 8 month-old WT and 
tgHD DG 24 hrs after BrdU injection; scale bar, 50µm. Quantitative analysis of (B) 
number of BrdU clusters, (C) size of BrdU clusters, (D) number of BrdU labelled cells  
within a cluster. Data presented as means±SD, Student t-test for statistical analysis. 
Note that in tgHD DG the number of proliferating units is reduced in 8 month-old 
(*p<0.05) and 12 month-old (**p<0.001) rats, however, size of the clusters (*p<0.05) 
and number of BrdU labelled cells within a cluster (*p<0.05) are increased 
specifically in 8 month-old tgHD rats. E) Quantitative analysis of BrdU labelled cells 
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in proliferating units that co-localize with DCX for neuroblast proliferation in WT and 
tgHD DG 24 hr after BrdU injection (8 months). Note the significant increase of BrdU 
labelled cells expressing DCX in the tgHD DG (***p<0.0001). F) and G) quantitative 
analysis of the percentage of the total amount of DCX positive cells in WT and tgHD 
DG in 8 month-old (F) and 12 month-old (G) rats. Note that in tgHD DG percentage 
of DCX positive cells is significantly enhanced in the 8 month-old rats (**p<0.001), 
while in the DG of 12 month-old tgHD the percentage of DCX positive cells is 
significantly reduced (**p<0.001). H) DCX positive cells in 8 month-old WT and tgHD; 
scale bar, 50µm. Insets are higher magnifications of the selected fields. Note the 
increased numbers of DCX positive cells and expression of DCX in the tgHD in 
axons in the hilar region (H). N=4 for WT and N=8 for tgHD.  
 
 
4.11. Reduced cell proliferation in tgHD animals correlates with increased TGF-
beta1 signaling in hippocampal stem cells 
 Wachs et al., recently demonstrated that TGF-beta1 impairs neural stem and 
progenitor cell proliferation, a finding also substantiated by other studies 58, 82, 91. 
Moreover, in a comparative transcriptome analysis, we showed that mRNA 
expression of TGF-beta1, as well as the TGF-beta downstream effector elements 
Smad2 and Smad4, and the TGF-beta inducible extracellular matrix (ECM) 
components were elevated in human HD brains71. This line of evidence points 
toward the elevation of TGF-beta signaling in tgHD hippocampus, thereby providing 
an explanation for the reduced stem cell proli feration. TGF-beta signaling was 
therefore assessed by immunohistochemistry for phospho-Smad2, an intracellular 
TGF-beta downstream effector molecule57, in the DG. A more specific focus was 
placed on Sox2 and GFAP/Sox2 double positive neural stem cells located in the 
SGZ.   Confocal analysis for pSmad2 immunoreactivity in the DG of WT rats revealed 
that pSmad2 staining was weak and confined almost exclusively to NeuN positive 
cells within the GCL (Fig. 4.15). In addition, DCX-expressing cells presenting a 
mature morphology, i.e. with extensive dendritic arborization, were also positive for 
pSmad2, while on the other hand DCX cells localized in the SGZ within clusters or 
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displaying an immature morphology were negative for pSmad2 (Fig. 4.15). 
GFAP/Sox2 double-labelled cells in the SGZ were virtually devoid of pSmad2 
immunoreactivity (Fig. 4.15).  
 
                                
Fig .4.15. Enhanced TGF-beta1/Smad2 signaling in tgHD rats.  
A) Presence of pSmad2 in 8 month-old WT DG granule cells. PSmad2 (green) is 
present in NeuN (blue) expressing cells and in mature DCX (red) positive cells (DCX 
cells in the granule cell layer presenting a dendritic tree perpendicular to the SGZ), 
but not in immature DCX positive cells (cells in clusters with a less pronounced 
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dendrite); scale bar, 50 µm. Insets are higher magnifications of arrowed fields. B) 
Presence of pSmad2 (green) in Sox2 (red) / GFAP (blue) double positive cells in 12 
month-old tgHD SGZ, but not in WT SGZ; scale bar, 50 µm. Insets are higher 
magnifications of the selected fields. C) Quantitative analysis of Sox2 and 
Sox2/GFAP double labelled cells that are positive for pSmad2 in 12 month-old WT 
and tgHD. Note the significant increase in Sox2 positive cells (***p<0.0001) and of 
Sox2/GFAP double positive cells (***p<0.0001) that co-localize with pSmad2 in 12 
month-old tgHD. Data as means±SD; one-way analysis of variance-Tukey post hoc 
for statistical analysis. N=4 for WT and N=8 for tgHD. D) Western blot demonstrating 
increased levels of pSmad2 in tgHD hippocampi. Smad2 and Actin are used as 
controls. 
 
 In contrast, 8 month-old (data not shown) and even more pronounced in 12 
month-old tgHD rats, the global pSmad2 staining-intensity was elevated in cells of 
the GCL (Fig. 4.15). Strikingly, overt pSmad2 immunoreactivity was present in 
GFAP/Sox2 double-labelled cells of the SGZ of 8 months (data not shown) and even 
stronger of 12 months tgHD rats (Fig. 5B). In addition to staining intensity, the 
number of Sox2-positive cells and of Sox2/GFAP- positive cells in the SGZ cells that 
co-labelled for pSmad2 was significantly enhanced in the tgHD rats (Sox2/pSmad2: 
WT: 20 ± 2.2% vs. HD: 56 ± 7.7%; Sox2/GFAP/pSmad2: WT: 18.5 ± 1.9% vs. HD: 
42.2 ± 8.7%) (Fig. 4.15). Western blot analyses confirmed the global increase in 
Smad2 phosphorylation in the tgHD hippocampus (Fig.4.1 5).  
 In order to substantiate our observations on the impact of TGF-beta signaling 
on the neural stem cell niche in HD pathology, we analysed the hippocampus of 
R6/2 mice, another well-characterized model for HD144.  At 9 weeks of age, cell 
proliferation in the R6/2 DG was significantly reduced as demonstrated by a 
decrease in the number of PCNA immunoreactive cells (Fig. 4.16, see also 149. This 
correlated with elevated levels of pSmad2 immunoreactivity in the DG of R6/2 mice 
as compared to WT mice (Fig. 4.16). Moreover, while there was virtually no pSmad2 
labelling in GFAP/Sox2 double-positive cells in the SGZ of WT mice, this putative 
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stem cell population showed strong immunoreactivity of pSmad2 in R6/2 animals 
(Fig. 4.16).  
                              
Fig.4.16. Reduced proliferation is associated with elevated TGF-beta1 
signaling in R6/2 mice. 
A) Quantitative analysis of the number of PCNA positive cells in the DG of 9 week-
old WT and R6/2 mice. Data are expressed as means ± SD. For statistical analysis a 
Student t-test was performed. Note the reduction of PCNA positive cells in R6/2 DG 
(**p<0.001). B) pSmad2 staining in the DG of WT and R6/2 animals. Note the 
prominent immunoreactivity of pSmad2 in R6/2 DG; scale bar, 100µm. C) Co-
localization of pSmad2 (green) immunoreactivity in Sox2 (red) and GFAP (blue) 
double positive cells in the hippocampal stem cell niche of WT and R6/2 mice; scale 
bar, 100µm. Note that pSmad2 is strongly present in Sox2/GFAP double positive 
cells specifically in R6/2 mice but not in in WT.  
 
 Next, we confirmed that an elevated TGF-beta level in the brain per se was 
sufficient to provoke the appearance of pSmad2 in the hippocampal stem cell niche. 
To this end, we infused TGF-beta1 into the lateral ventricle of WT rats for 14 days 
and analyzed cell proliferation and the pattern of pSmad2 staining in Sox2 positive 
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cells. As we and others reported previously82, 91, TGF-beta1 infusion induced a 
strong inhibition of proliferation in the hippocampal DG (CSF: 689± 40.6 vs. TGF-
beta1: 293±31.8) (Fig. 4.17). This proliferative decline was associated with an 
increase in the number of Sox2-positive cells (Fig. 4.17). As in naïve WT rats, 
pSmad2 was weakly but consistently present in cells of the GCL and absent in the 
Sox2/GFAP-positive cells of aCSF-infused rats (Fig. 4.17). In contrast, the infusion of 
TGF-beta1 in WT rats enhanced the staining intensity of pSmad2 in the GCL and 
induced the presence of pSmad2 in Sox2/GFAP double positive cells of the SGZ 
(Fig.4.17) with a similar pattern as observed in the tgHD rats. Moreover, TGF-beta1 
induced a fast appearance of pSmad2 in adult rat-derived neural progenitors in an ex 
vivo situation (Fig.4.17) indicating that these cells are responsive to TGF-beta1.  
 Finally, we determined if TGF-beta1 indeed provokes a cell cycle arrest in 
neural progenitors. For that, we stimulated neural progenitors derived from the adult 
rat hippocampus 82 in vitro with TGF-beta1 and analyzed the cell cycle phases by 
Ki67/PI flow cytometry. This method allows the dissection of G0 and G1, since Ki67 
is expressed throughout the cell cycle except in G0155. The quantitative analysis 
revealed that a 7 day treatment with TGF-beta1 induced a shift to G0 phase of the 
cell cycle (G0: ctrl, 24.8±3% vs. TGF-beta1, 38,5±2.7%; indicating that TGF-beta1 
induces neural progenitors to exit the cell cycle and to become quiescent.  
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Fig.4.17. TGF-beta1 directed proliferation and cell cycle arrest is associated 
with enhanced SMAD2 signaling in stem cell niche. 
A) Quantitative analysis of number of BrdU positive cells in the DG of TGF-beta1 and 
aCSF infused rats. Data is expressed as means ± SD. For statistical analysis a 
student test was performed. Note that in TGF-beta1 infused rats, the number of BrdU 
positive cells is significantly reduced (***p<0.0001). B) Sox2 immunoreactivity in the 
DG of aCSF and TGF-beta1 infused animals. Note the prominent immunoreactivity 
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of Sox2 in TGF-beta1 infused DG; scale bar, 50µm. C) confocal analysis of Sox2 
(red) and GFAP (blue) double positive cells that colocalize pSmad2 (green) in the 
DG of CSF and TGF beta1 infused animals; scale bar, 50µm. Insets are focused on 
the selected fields. Note the prominent expression of pSmad2 in Sox2/GFAP double 
positive SGZ cells in TGF-beta1 infused animals, while CSF infused animals do not 
present pSmad2 in Sox2/GFAP positive cells. D) Western blot analysis 
demonstrating TGF-beta1 induced phosphorylation of Smad2 in neural progenitor 
cultures. Smad2 and Actin as controls. E) Quantitative analysis of Ki67/PI flow 
cytometry of neural progenitors demonstrating a TGF-beta1 induced cell cycle phase 
shift into G0 (**p < 0.01). For statistical analysis a student test was performed. 
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5. Discussion  
 
 This thesis addressed the possible role of TGF-beta signaling in the 
hippocampal stem cell niche of the healthy and the disease brain, in particular of the 
HD brain. This study provides: 1) a complete profile of the receptor mediated TGF-
beta1 signaling in the intact rat adult brain, 2) the evidence for functional role of TGF-
beta1 signaling in the stem cell maintenance, neuronal differentiation and 
neuroprotection in the adult rodent brains and 3) the proof of stem cell quiescence 
and impaired neurogenesis in the hippocampus of Huntington‟s disease animal 
models which we correlated with enhanced TGF-beta1 signaling. 
TGF-beta1 signaling the intact adult rat brain  
 This study demonstrates that the normal adult rat brain displays an active 
level of TGF-beta signaling. The immunohistrochemistry and Western bloting 
methods confirmed the expression of TGF-betaRI, TGF-betaRII and phosphorylated 
status of Smad2 throughout the normal adult rat brain including neurogenic areas. 
This finding validates previous study that indicated an overall high level of TGF-beta 
signaling in the brain of SBE luciferase mice85. This suggest the presence of 
physiological TGF-beta1 levels in most  brain areas164, 165.  
Role of TGF-beta1 in stem cell maintenance of the adult brain    
 For the expression of pSmad2 in the hippocampal neurogenic niche, the co-
immunostainings and confocal microscopy methods revealed that the NSCs 
population that are in proliferative phase failed to expresse pSmad2. However, 
quiescent stem cells displayed strong pSmad2 signal as indicated by PCNA and 
pSmad2 co-immunostainings with Sox2 or GFAP. There, the PCNA negative fraction 
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of Sox2 or GFAP expressing stem cells showed a strong nuclear appearance of 
pSmad2. An over-expression or infusion of TGF-beta1 in the adult rodent brains 
inhibited the proliferation of NSCs in the hippocampus and the SVZ.82, 91. This 
present study also confirmed the previous reports however by using TG TGF-beta-
on mice that over-expressed TGF-beta1 in the hippocampus under the tet- regulated 
system 148. A two month periods of TGF-beta1 induction by doxycycline withdrawal 
(TGF-beta1-on mice) inhibited NSC proliferation as seen by reduced number of 
PCNA positive cells in the hippocampal DG compared to doxycycline treated 
animals(TGF-beta1-off mice). Doxycycline withdrawal induced the elevation of 
pSmad2 in the SGZ Sox2/GFAP expressing NSCs in the hippocampus of TGF-beta-
on mice. Thus, a crucial role of TGF-beta1 in the adult hippocampal niche is to 
control the balance between the quiescent and proliferating NSCs, thereby 
modulating the stem cell potential and to avoid the stem cell depletion in the stem 
cell niche of the adult brain.  Further, in vitro studies using neurophere cultures 
derived from the adult rat hipocampus provided an authentication of receptor 
mediated TGF-beta1 activation on these cells as demonstrated by Western blot and 
immunocytochemistry. TGF-beta1 stimulation in neurospheres induced a high level 
phosphorylation of Smad2 at 2 hrs and increased nuclear translocalization of the 
pSmad2 including in differentiated stem and progenitor cells. Moreover, one-week 
incubation of neurosphere cultures with TGF-beta1 inhibited cell proliferation and 
promoted cell cycle exit. The cell cycle exit is a primary requisite for quiescence and 
this could be a protective mechanism involved to balance stem cell depletion in the 
adult brain. It has been reported that TGF-beta1 promotes the cell cycle exit by 
inducing the expression of the cell cycle protein, p2182, 166. Therefore, TGF-beta1 
induced activation of smad2 phosphorylation in the proliferating NSCs would be a 
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key molecular event to achieve stem cell quiescence in the adult brain. This induced 
stem cell quiescence could be a consequence of seizing the proliferating NSCs in 
brain pathologies associated with a prompt elevation of TGF-beta1. 
TGF-beta1 promotes neuronal differentiation and survival in the adult brain. 
 In addition to the TGF-beta1 induced anti proliferative effect on NSCs in the 
adult brain, the present work also demonstrates the involvement of TGF-beta1 in 
neuronal differentiation and neuronal survival. As observed from co-
immunofluorescence staining, TGF-beta signaling is active predominately in cells 
with neuronal commitment and neuronal identity as indicated by increased 
percentage of pSmad2 colocalization with DCX and NeuN positive neurons. In the 
adult stem cell niche while pSmad2 expression is low in the young immature DCX 
positive cells, pSmad2 localization is increased in the morphologically matured DCX 
expressing neurons as demonstrated by co immunostainings of PCNA, pSmad2 and 
DCX with morphological difference. The increased accumulation of pSmad2 from the 
proliferating DCX sub-population to the morphologically matured DCX positive 
neurons might be a crucial event for neuronal differentiation and subsequent 
integration in to neuronal circuit. In consistent nearly all NeuN positive matured 
neurons in the hippocampal DG displayed a strong signal for pSmad2 in their 
nucleus. It has been demonstrated previously that newly born DCX expressing cells 
ultimately turn into NeuN positive neurons in the hippocampal DG of the adult 
brain150. The analysis of neuronal differentiation in the hippocampus of TGF-beta-on 
mice indicated that the number of surviving cells 4 weeks after BrdU labelling was 
increased. Thus, even though a reduced number of cells were generated after TGF-
beta1 over-expression, the survival of newly generated cells was dramatically 
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increased resulting in a net gain of NeuN positive newly born neurons in the 
hippocampus of TGF-beta on mice. This is in agreement with data with previous 
reports showing increased neuronal differentiation and survival upon TGF-beta1 
induction in the adult brain93, 94. Vice versa, increased neuronal cell death has been 
observed in TGF-beta1 knockout mice167. Importantly, TGF-beta1 has been involved 
in the generation of dopaminergic neurons in the developing brains168. 
 
Neurogenesis and TGF-beta1 signaling in Huntington’s diseased brain 
 In the context of neurodegenerative disease, the present work demonstrates 
impaired progenitor proliferation associated with an increase in neural stem cell 
quiescence in animal models for HD (summarized in Fig. 5.1). TGF-beta1 signaling 
appears to be involved in triggering quiescence of stem cells, as suggested by the 
presence of pSmad2 in Sox2/GFAP-expressing SGZ cells in tgHD rats, R6/2 mice 
and after TGF-beta infusion, as well as by the TGF-beta1 induced cell cycle arrest in 
neural progenitor cultures. In 8 months old tgHD rats, i.e. in the early phase of the 
pathology, the deficit in stem cell proliferation was compensated by increased DCX-
expressing neuroblast proliferation, which resulted in an expansion of the DCX-
expressing cell population. Survival of newly generated cells, the total number of  
dentate gyrus neurons and neuronal density were also reduced in tgHD rats and 
correlated with weaker pCREB signaling (Fig. 4.12). Similar observations were 
previously reported for R6/2 mice98, 149, 169. Further evidence for a reduced pCREB 
signalling in HD was provided by expression profiling of human HD brains 
demonstrating a down-regulation of CREB-regulated transcription coactivator1, of 
p300/CBP-associated factor and of cyclic AMP-regulated phosphoprotein71 . 
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Fig.5.1. Schematic summary of modulation of neurogenesis at different cellular 
levels in the transgenic rat model of Huntington disease (tgHD).  
In 8-month-old tgHD animals, the deficit in stem/progenitor proliferation was 
compensated by doublecortin (DCX)-positive neuroblasts (red cells) resulting in an 
overall increase in the DCX population. In 12-month-old tgHD rats, reduced 
proliferation of progenitors was accompanied by a reduced number of DCX-positive 
cells. There were fewer surviving newly generated cells (round-shaped dark blue  
cells) in 8- and 12-month-old tgHD than in wild-type (WT) animals. The numbers of 
label-retaining quiescent subgranular zone stem cells, however, were elevated in 
tgHD animals. In WT, transforming growth factor-beta1 signaling (fluorescence green 
arrow) was confined to cells of granule cell layer (gray cells) and it was absent or low 
in the stem cell niche. In tgHD animals, however, the overall TGF-beta1 signaling 
was greater and prominent in the stem cell niche where it induced cell cycle exit and 
stem cell quiescence. 
 
Neural stem cell quiescence in neurodegeneration  
 One of the most striking findings of the present work is the pathology-induced 
quiescence of neural stem cells in the hippocampal stem cell niche. This quiescence 
was revealed by an expansion in the pool of label retaining, non-proliverative and 
undifferentiated cells that expressed in addition the stem cell maintenance marker 
Sox2. A number of studies have already investigated cell proliferation in the neural 
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stem cell niche of animal models of neurodegeneration and reported reduced 
progenitor proliferation rates. Hence, this proliferative decline was documented in the 
R6/1 and R6/2 HD mouse model 98, 169, 170 in the A53T mutant alpha-synuclein 
mouse model of Parkinson‟s disease 171, in a mouse model of Alzheimer's disease, 
which expresses the human amyloid precursor protein (APP) with the V717F 
mutation (PDAPP mice)172 and in the superoxide-dismutase 1 mouse model of 
Amyotrophic Lateral Sclerosis173. However, reduced neurogenesis under chronic 
neurodegenerative disease cannot be taken as a general rule, since cell proliferation 
in the subventricular zone of human HD brains and hippocampal neurogenesis in 
human AD brains is enhanced147, 174.  
 A reduction in the numbers of proliferating cells might result from i) a lower 
number of proliferation-competent stem/progenitor cells, ii) a slower proliferation 
rate, i.e. a prolonged cell cycle, or iii) a shift of stem cells from the proliferative status 
to quiescence. Our present findings strongly support the latter hypothesis, although a 
participation of the two other mechanisms cannot be excluded at this time point. It is 
now crucial to investigate if TGF-beta remodelling of the stem cell niche and 
induction of stem cell quiescence during the course of neuropathologies is a 
widespread phenomenon or restricted to a subtype of conditions, such as HD.  
Under physiological conditions, it is hypothesized that stem cells limit their mitotic 
activity and remain mostly in quiescence (G0) until a self-renewing cycle is required 
to maintain a steady state pool and to prevent stem cell pool depletion. While on one 
hand acute CNS lesions, such as stroke and quinolinic acid- or 6-hydroxydopamine-
induced striatal lesions, apparently provide a stimulus to foster stem and progenitor 
cell proliferation, probably in an attempt to compensate for the neuronal loss146, 171, 
175 slow progressive neurodegeneration on the other side often compromise 
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progenitors in their proliferative activity. Whether this inhibitory response serves a 
specific function or is a negative side-effect deriving from a disease-associated 
microenvironmental change, such as inflammatory responses, remains to be 
deciphered. But enhanced neural stem cell quiescence might well serve as a 
mechanism to maintain or to preserve the stem cell pool. Indeed, the potential to 
generate neurospheres from the R6/2 mouse is higher compared to WT animals94, 
and neural progenitors derived from HD mice demonstrate increased neuronal 
differentiation 176.  
 
TGF-beta1 signaling as a potential mechanism triggering stem cell quiescence 
in neurodgeneration  
 In the frame of several pathological conditions, acute or degenerative, 
inflammatory processes get activated and a plethora of anti- and pro-inflammatory 
cytokines, chemokines, neurotransmitters and reactive oxygen species are being 
released177. The individual pattern of inflammatory cells and cytokines present in the 
neural stem cell niche during a pathological state might modulate the molecular and 
cellular context of TGF-beta action and thereby might create apparently diverging 
TGF-beta-associated effects178. A well known example for this cellular context-
dependent Janus-head-like activity of TGF-beta is the fact that TGF-beta acts for 
most cells as an anti-mitotic cytokine, while it promotes proliferation of tumour cells 
on the other side58. This context-dependency might explain also conflicting data 
reporting enhanced cell proliferation in the subventricular zone in HD patients147 and 
diminished progenitor proliferation in the hippocampal neurogenic niche in HD 
animal models98, 149. We moreover demonstrated in this study that differences in 
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cellular response could even be documented between the putative stem cell and the 
neuronal progenitors.  
 Although the pathways induced by TGF-beta leading to neural stem cell 
quiescence requires further molecular investigation, mechanisms are likely to be  
similar to those previously described in other systems, in particular in the 
hematopoietic system. Observation in the latter system suggested that Pbx1 and 
Pbx1-dependent genes as well as FoxO3 could be effectors of the TGF-beta-
induced quiescence179, 180. FoxO3 is a central stem cell maintenance factor 
integrating a plethora of signaling cascades including the IL-2R/STAT pathway, the 
TGF-beta/Smad pathway, the PI3K/Akt/mTOR cascade, and Notch signal and is 
therefore likely to be involved in the signaling leading to neural stem cell quiescence 
181. 
 
What is the impact of the huntingtin transgene expression in neural stem cell 
biology in tgHD rats?  
 In addition to the microenvironment-induced effects on neural stem cell 
proliferation, the expression of the huntingtin transgene in our animal models might 
exert cell-intrinsic activities contributing to the cell cycle exit and quiescence. A pre-
requisite for this however is that the huntingtin transgene gets expressed in neural 
stem cells. Along the course of the present study, we performed immunodetection for 
endogeneous and/or transgenic huntingtin using the IC2 and EM48 antibodies in the 
tgHD rats. However, we could not detect any immunoreactivity in the hippocampal 
neural stem cell niche (data not shown).  
 Previously, an increasing expression of the huntingtin protein between 9 and 
15 months of age, occurring specifically in mature neurons was reported132. Also, our 
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analysis of R6/2 mice revealed that mutant huntingtin protein was only present in 
mature hippocampal granule cells, but not in neuronal precursors or neural stem 
cells149. Interference with the neuronal maturation process by the mutant and 
aggregated huntingtin could thus explain the diminished survival of newly generated 
neurons. Although it cannot be excluded that the presence of minute amounts of 
huntingtin protein negatively affects neural stem cells proliferation, the main 
mechanism by which HD reduces neurogenesis appears to proceed via a 
remodelling of the stem cell niche microenvironment.  
 In conclusion, the present study demonstrates that neurogenesis in tgHD rat 
hippocampus is impaired via mechanisms acting at different levels along the 
generation of new mature neurons. Our evidence supports the hypothesis that 
defects in progenitor proliferation and cell cycle exit are orchestrated by TGF-beta 
signaling in the local microenvironment. 
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6. Summary  
 In the adult brain, new neurons are continuously produced in the subgranular 
zone (SGZ) of the hippocampus and in the subventricular zone (SVZ) of the lateral 
ventricles. This process includes neural stem and progenitor cell maintenance, 
proliferation, neuronal differentiation, integration and survival. These neural stem cell 
niches are composed and regulated by its cellular, extracellular matrix and cytokine 
profile. However, the sequence of cellular events and exact molecular mechanisms 
that control neurogenesis in normal and neurodegenerative brain are mostly 
unknown. Transforming growth factor-(TGF) beta1 signaling has been implicated in 
regulating the stem cell pool during midbrain development, where it controls stem 
cell proliferation. In the adult brain, it has been demonstrated that experimentally 
induced levels of TGF-beta1 blocks neural stem and progenitor cell proliferation. 
Interestingly, adult neurogenesis is inhibited in neurodegenerative disorders such as 
Huntington‟s disease (HD) but the progression of cellular events and molecular 
mechanisms that manipulate neurogenesis in the HD brain are poorly understood. 
Surprisingly, the expression of TGF-beta1 and TGF-beta signaling components are 
elevated in the degenerating HD brain. Therefore, this study investigated 1) the TGF-
beta1 signaling in the adult neural stem cell niche under physiological and healthy 
conditions, 2) the regulation of hippocampal neurogenesis in the brains of a TGF-
beta1 inducible trangenic animal model (TGF-beta-on mice), 3) the regulation of 
neurogenesis in transgenic HD models (tgHD rats and R6/2 mice) at different clinical 
phases and 4) evaluated a possible correlation between the observed neurogenic 
modulations and alterations in TGF-beta signaling by performing a comprehensive 
histological study of TGF-beta1 signaling components in quiescent and proliferating 
neural progenitors and their progeny.  
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 Results revealed that TGF-beta1 signaling is virtually absent in proliferating 
stem cells but progressively active in post-mitotic neurons in the hippocampal stem 
cell niche of the healthy adult brain. An experimentally induced TGF-beta1 level in 
the hippocampus of TGF-beta1-on mice activates phosphorylation of the 
downstream signaling component Smad2 in stem cells followed by reduced 
proliferation of stem and progenitor cells. Moreover, the induced level of TGF-beta1 
promoted survival of newly born neurons in the hippocampus of TGF-beta1-on mice. 
In the tgHD brains, we encountered a disease-associated progressive decline in 
hippocampal progenitor proliferation accompanied by an expansion of the pool of 
BrdU-label-retaining Sox2 positive quiescent stem cells. This has been associated 
with accumulation of pSmad2 in Sox2/GFAP expressing stem cells in the 
hippocampus of tgHD animals. These results indicate that alterations in 
neurogenesis in tgHD animals occur in successive phases that are associated with 
increasing TGF-beta1 signaling. Thus, TGF-beta1 signaling appears to be a crucial 
modulator of neurogenesis in healthy and HD brains. 
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